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Humans are complex organisms, comprised of many tissues, which are 
comprised of different cell types.  Modern single cell sequencing technologies allow 
scientists to interrogate epigenetic, genetic and transcriptional profiles of single cells, 
and challenged them to re-evaluate the meaning of cell type.  In this thesis, I define cell 
type based on clustering of single cell transcriptional and epigenetic signatures-- cells 
with similar molecular signatures share a common cell type, while cells with different 
signatures have different cell types.  I use this definition to characterize multiple distinct 
cell types in normal and tumor tissues. 
  xii 
In the first half of this thesis, I describe an analysis workflow that I optimized for 
single nuclear RNA-seq. I assess its biological interpretability by analyzing deeply 
characterized human and mouse brains, and then apply it to a less characterized 
tissue—human heart ventricles.  I demonstrate my method’s ability to capture rare and 
meaningful biological cell subtypes, and describe differences between the right and left 
ventricles of human hearts at the single cell level.   
Next I use this method to analyze flash frozen tumor sections from five 
glioblastoma patients.  In this study, I combine single nucleus RNA sequencing (snRNA-
seq) with single cell open chromatin profiling data (snATAC-seq).  By combining these 
two single cell technologies, we can confidently identify cells carrying copy number 
variation in tumor samples, ask which of these copy number changes are represented 
at the transcriptomic level, and ultimately characterize the observed inter- and intra-
patient heterogeneity. 
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CHAPTER 1: Introduction 
Over the course of my PhD I have transitioned from analyzing populations of 
cells (bulk data) to analyzing single cells. I began my PhD research analyzing 
epigenetic modifications, specifically base-resolution hydroxymethylation data, with the 
goal of understanding this modification’s role in gene regulation.  Attempting to integrate 
such epigenomic data with other high-throughput molecular assays: RNA-seq, whole 
genome bisulfite sequencing (WGBS), ChIP-seq and ATAC-seq data in adult tissues, I 
realized that my observations likely represented the biology of the predominant cell type 
in each tissue.  Therefore, I focused my efforts on learning how to analyze single 
nuclear RNA-seq (snRNA-seq) data.  After analyzing snRNA-seq profiles in normal 
human brain, normal mouse brain, and normal human heart samples, I had the 
opportunity to apply my skills to a more translational project—characterizing flash frozen 
glioblastoma sections for which open chromatin and transcriptional signatures were 
profiled at the single cell level. 
 1.1 Single Nuclear RNA-seq 
Single cell sequencing (DNA and RNA) was chosen as Nature Method’s “method 
of the year” in 2013.  At the time, this choice was motivated by the potential of this 
technology to uncover tissue heterogeneity, understand the differences between healthy 
and disease tissues, and to profile rare cell types1.  Since 2013, many better single cell 
techniques have been created to profile cells at the transcriptional level, and large scale 
efforts are underway to essentially create a “reference human cell atlas ” for different 
cell types2,3.  
The characterization of so many transcriptomes called for a redefinition of cell 
type. Several scientists in the field were asked to define this seemingly common notion, 
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and their answers varied from redefining cells based on cellular states, to cellular 
lineages (“cell history”), to grouping cells based on their function within tissues4. While 
there is no agreement on how exactly cell type should be defined, researchers in the 
field do agree that defining a cell’s type by its unique transcriptional profile is only one 
component of that cell’s identity.  
Single nuclear methods were developed shortly after the now ubiquitous whole-
cell methods to perform transcriptomic sequencing at the single cell level5–10.  Single 
nuclear methods isolate and sequence only nuclear RNA, thereby capturing nascent 
transcription.  While the nucleus contains only 10% of the cell’s mRNA, making snRNA-
seq data sparser than scRNA-seq data, single nuclear methods can be more readily 
performed on frozen tissues, and can capture cell types that are rare or difficult to 
dissociate from a solid tissue.   
 Due to this sparsity, a few studies have focused on demonstrating that the 
transcriptional diversity captured in snRNA-seq data is sufficient, and in some cases 
even more comprehensive in capturing the heterogeneity observed when performing 
scRNA-seq11–13.  Bakken et al compared 463 cells to an equal number of nuclei from 
the adult mouse brain (primary visual cortex) to show that they could capture the same 
eleven cell types in both assays, and that gene expression levels derived from reads 
mapping to introns from snRNA-seq data shared a strong correlation with gene 
expression levels in single cells11.  Lake et al also showed that snRNA-seq results were 
consistent with scRNA-seq results of mouse neurons; however, gene expression was 
concordant for cell type specific and metabolic genes, but not genes enriched for 
mitochondrial respiration in these cells 12.  Wu et al showed that snRNA-seq could be 
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used to capture rare cell types in non-neuronal cells (adult kidney), and did not capture 
transcriptional heterogeneity associated with stress, which is likely believed to be an 
experimental artifact introduced by the tissue dissociation process13.  
Over the years, single cell transcriptomic assays have scaled exponentially in 
throughput, while the cost of these technologies has significantly dropped14.  While 
single cell RNA-seq may be preferred to capture certain cell types, such as those with a 
large cytoplasmic fraction, or to perform certain computational techniques to answer 
questions about unbiased developmental trajectories,15 single nuclear RNA-seq may be 
necessary to capture rare cell types or to work with frozen tissue. This makes snRNA-
seq an excellent candidate to study normal and tumor frozen tissues.  In my thesis I use 
snRNA-seq to profile flash frozen tissues from normal tissues (adult mouse forebrain, 
human frontal cortex, hippocampus and heart ventricles) and tumor sections 
(glioblastomas).   
1.2 Glioblastoma Heterogeneity  
 Glioblastoma (GBM) is the most common and aggressive brain tumors with 
median survival of 12 to 15 months.  Common interventions such as chemo-, and radio-
therapies have immunosuppressive effects and even surgical excision of the tumor has 
not shown prolonged success16.  Furthermore, patients who have shown recurrence of 
glioblastoma following treatment usually only live for 6-9 more months, and most do not 
receive a secondary treatement17.  The lack of success in GBM treatment can be 
attributed to the physical and molecular heterogeneity of GBM.  
 The most comprehensive attempt to characterize the molecular heterogeneity in 
GBM was undertaken by The Cancer Genome Atlas18,19. Their pilot study identified 
three pathways (receptor tyrosine kinase signaling, p53 signaling, and RB signaling) as 
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core pathways mutated in GBM18.   Soon after, four molecular subtypes of GBM 
(proneural, neural, mesenchymal and classical) were defined by a set of 840 genes19.  
GBMs of the classical subtype commonly show amplification of EGFR and express 
neural precursor and stem cell markers. The mesenchymal subtype highly expresses 
both mesenchymal and astrocytic markers, has the worst survival of the four subtypes, 
and its microenvironment has been shown to be enriched for tumor promoting M2 
macrophages20.  The proneural subtype carries mutations in PDGFRA and IDH1, highly 
expresses oligodendrocyte development genes, and is associated with the best patient 
outcomes due to frequent mutation of IDH121.   
 With the increasing affordability and throughput of single cell technologies, 
several studies have used the single cell lens the characterize GBM heterogeneity.  In 
one of the first single cell transcriptomic profiling studies of GBM, cells within five GBM 
tumors carried a mixtures of signatures from the four molecular subtypes previously 
defined22.  Additionally, among these five patients, an increase in molecular 
heterogeneity within a given tumor was associated with worse survival.  Single cell DNA 
profiling in GBM has also been used to reveal clonal sub populations and to 
characterize differences between cells with varying proximity to the tumor core23,24  
More recently, a study attempting to investigate the glioblastoma cell of origin used 
single cell sequencing to show that cells carrying mutations in the tumor free 
subventricular zone (SVZ) of a patient’s brain can give rise to the glioblastoma tumor25.  
 Our current understanding of GBM inter/intra-tumoral heterogeneity is focused on 
the transcriptomic and genomic aspects, and is insufficient for creating successful 
therapies26.  To address this gap, the epigenetic intra-tumoral heterogeneity of GBM, 
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specifically the open chromatin profile, needs to be characterized.  ATAC-seq is an 
epigenetic assay that can reveal active regulatory elements by profiling open 
chromatin27.  The utility of this assay has increased after several approaches 
computationally linked active regulatory elements to their target genes at the single cell 
level28,29.  While ATAC-seq has been used to characterize GBM at the bulk level, it has 
yet to be applied to GBM at the single cell level27,30. In my thesis, I combine single 
nuclear profiling of RNA and open chromatin in flash frozen tumor sections, from five 
GBM patients, to characterize inter and intra patient heterogeneity.  
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CHAPTER 2: Using intronic reads to deconvolve frozen tissue samples from 
human heart, and human and mouse brain by single nucleus RNA-seq 
 
2.1 Abstract 
Single cell (scRNA-seq) and single nuclei RNA-seq (snRNA-seq) are powerful 
tools to dissect tissue heterogeneity. Isolation of intact cells, like neurons and 
cardiomyocytes, from frozen tissues is very challenging; however, tissues are amenable 
to isolation of intact nuclei. In this study, we generated snRNA-seq profiles for ~24,000 
single nuclei from flash frozen brain and heart tissues. SnRNA-seq profiles are 
significantly sparser than those generated from scRNA-seq, and nuclear transcriptomes 
can be biased by spliced cytoplasmic RNA molecules originating from highly expressed 
genes, which stick to nuclei of other cells. By using a customized computational 
workflow and focusing on intronic reads for nuclear clustering analysis, we overcome 
these limitations, and digitally dissect adult mouse forebrain, adult human frontal cortex 
and hippocampus, and human cardiac left and right ventricles. Interestingly, our intronic 
read based clustering approach increases sensitivity and sub-clustering for both brain 
and heart tissues compared to clustering approaches that use exonic reads or a 
combination of exonic and intronic reads.  Moving forward, this approach could be 
useful for unbiased characterization of a variety of frozen biobanked clinical samples 
from control and diseased patients. 
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2.2 Introduction 
Single cell RNA-seq (scRNA-seq) is a powerful tool to dissect tissue 
heterogeneity1–5.  However, it is challenging to perform scRNA-seq on primary human 
tissues since these samples are typically preserved by flash freezing, making it either 
impossible or extremely difficult to isolate intact cells, like neurons or cardiomyocytes, 
from frozen tissue specimens. Additionally, isolation of cells often requires enzymatic 
digestion of tissue that can alter the transcriptome. Nuclei, on the other hand, are more 
stable, and amenable to isolation from frozen tissues using mechanical tissue 
homogenization. 
Recently, multiple single nuclei RNA-seq (snRNA-seq) experimental protocols 
have overcome these hurdles in a variety of tissues (Supplementary Table 1) 2,4–13 Each 
of these protocols has its own advantages; of note, droplet based protocols from 10x 
genomics are easy to implement and demonstrate high cell recovery, and protocols 
such as SPLiT-seq are able to sequence up to a million cells in one experiment using 
combinatorial barcoding based approaches 2,14.  Furthermore, 3’ counting based 
approaches have improved transcript quantification by implementing unique molecular 
identifiers (UMIs), which can differentiate between pcr duplicates and true transcript 
copies.  Full-length transcript profiling protocols have also been created, and they have 
tackled hurdles related to genome coverage.  These protocols allow for deep 
characterization of each cell with the caveat of lower cell numbers that can be 
processed in parallel, and the inability to incorporate UMIs (Supplementary Table 1)15.  
For some experiments snRNA-seq is necessary to profile specific cell types in a 
tissue; however, it is also important to know if these profiles are comparable to scRNA-
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seq profiles.  Recent studies have not only shown comparable transcriptomic profiles 
between cells and nuclei isolated from frozen biopsies, but have also suggested that 
snRNA-seq can sometimes be a less biased approach when trying to profile cells that 
are easily ruptured in the single cell isolation process16–18.   When used to profile the 
adult kidney, for instance, snRNA-seq not only captured a greater number of cell types 
than scRNA-seq, but also, lacked transcriptional signatures associated with stress, 
which are likely the byproduct of the tissue dissociation process18.  
While many challenges in the experimental design of isolating and sequencing 
transcriptomes of nuclei have been addressed, computational challenges that arise from 
sequencing the nucleus, rather than the whole cell, are only beginning to be addressed 
12,16,17.  Since nuclei contain about 10% of a cell’s total RNA, data generated from single 
nuclei versus single cells are sparser.  Additionally, the number of reads mapping to 
intronic regions can be higher than those mapping to exonic regions, due to the 
abundance of unspliced nascent RNA in the nucleus.  In order to address the sparsity of 
the data and increase the information content that each cell can provide, several recent 
studies have incorporated both intronic and exonic reads when analyzing single nuclear 
transcriptomic data12,16,17.  Apart from capturing an unspliced nascent RNA in the 
nucleus, snRNA-seq also captures free floating, cytoplasmic, highly expressed, spliced 
RNA transcripts. Current studies interpreting snRNA-seq data do not discuss how to 
deal with the erroneous signal from these spliced RNA transcripts.   
Computational analysis of single cell or single nuclear transcriptomic data 
typically involves a workflow that starts with quality control, and ends with unsupervised 
clustering of individual cells in order to resolve cell types19.  In this study we optimize the 
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computational workflow for snRNA-seq data, and profile frozen human cardiac left and 
right ventricular tissue, adult human frontal cortex and hippocampal tissue, and adult 
mouse forebrain tissue. Specifically, we address the issue of free floating, cytoplasmic, 
highly expressed, spliced RNA transcripts by using only intronic reads to inform the 
unsupervised clustering of individual cells; due to the aforementioned data sparsity of 
snRNA-seq data, we quantify gene expression in ~24000 single nuclei using intronic 
and exonic reads. Using this approach we digitally dissect the cellular composition of 
brain and heart tissues.   
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2.3 Results 
snRNA-seq analysis of adult mouse forebrain recapitulates spatial neuronal 
heterogeneity and reveals neural stem cell like cell populations 
A well established but labor-intensive method to isolate nuclei from frozen brain 
tissue is to use dounce homogenization in combination with density gradient 
centrifugation 20. Therefore, we asked if isolating nuclei by grinding brain tissue using a 
mortar and pestle, followed by permeablization, would provide a straightforward 
alternative to nuclei isolation. Using this strategy, we performed single nucleus RNA-seq 
analysis of frozen forebrain tissue isolated from 8 week old mice for two biological 
replicates (P56, Fig. 1, Supplementary Fig 1a-c).   
In total, 9,137 nuclei from both replicates (3,719 and 5,418 nuclei respectively) 
passed quality filtering (see methods). Since the number of transcripts detected in 
single nuclei is lower than that of single cells, we modified the computational analysis 
workflow for scRNA-seq to account for the data sparsity  (see methods). We used 
sparse singular value decomposition to reduce the dimensions of the expression matrix 
(Supplementary Fig. 1d). Due to the abundance of unspliced transcripts, more than half 
of sequenced nuclear RNA is comprised of intronic RNA molecules. Furthermore, free-
floating cytoplasmic mRNA molecules of highly transcribed genes are potential sources 
of noise and background signal in clustering analyses of snRNA-seq data.  In order to 
account for this, we performed clustering using only intronic reads (see methods, 
Supplementary Fig 2a-c). Due to data sparsity we combined both intronic and exonic 
reads to recover more transcripts and include single exon genes when performing 
differential expression analysis 12.  As expected, genes which are recovered when 
adding back in exonic reads are primarily those with a larger 3’ end or those with a 
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single exon (Supplementary Fig 2d).  Using this workflow, we detected on average 620 
genes and 1,074 transcripts per nucleus for the two replicates 
We identified 14 distinct clusters representing major cell classes including 
excitatory neurons, inhibitory neurons, oligodendrocytes (ODG), oligodendrocyte 
progenitor cells (OPC), astrocytes (AC), and microglia based on marker gene 
expression and gene ontology analysis 3,21(Fig. 1a,b,c, Supplementary Table 2). In 
addition, the identified cell clusters and their transcriptional signatures from our analysis 
were comparable to data generated by DroNc-seq in the mouse hippocampus and 
cortex (Fig. 1d)11. 
To understand the depth of neuronal heterogeneity we could capture, we first 
annotated 6 excitatory and 3 inhibitory neuron clusters based on expression of Slc17a7, 
encoding the vesicular glutamate transporter 1, and Gad1, encoding glutamate 
decarboxylase 1 (Fig 1a,b). Since the forebrain encompasses multiple functionally 
distinct brain regions like the cerebral cortex, hippocampus, striatum, olfactory bulb and 
thalamus, we asked if the neuronal clusters represent different brain regions. Further 
analysis of these clusters readily revealed cluster specific expression of genes for each 
of the excitatory neuron clusters, enabling us to assign them to cortical layers 2-4 
(cluster-specific gene: Enpp2) , layers 4-5 (Rorb), layer 6 (Ctgf, Foxp2) , hippocampal 
regions CA1/3 (Neurod6) , the dentate gyrus (DG) (C1ql2) , and the thalamus  (Prkcd) 
(Fig. 1a-d, Supplementary Table 2) 3,21,22. 
We then identified four main clusters of inhibitory neurons (MSN, IN1, IN2, INOB) 
(Fig. 1a, b) 3,21,22. One of these clusters, showed high expression of Ppp1r1b, encoding 
the Protein Phosphatase 1 Regulatory Inhibitor Subunit 1B, a marker for medium spiny 
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neurons in the striatum (MSN, Fig. 1a, Supplementary Fig. 1b).  IN1, however, showed 
high expression for genes associated with inhibitory neurons of the olfactory bulb 
(Meis2, Cpa6) (Fig 1a) 3,21.  To delineate the heterogeneity of the largest inhibitory 
neuron cluster, IN2, we performed another round of clustering focusing on these nuclei. 
This second round revealed eight sub-clusters of which four showed specific expression 
of canonical marker genes of inhibitory neuron subtypes like Vip, Calb2 and a mixture of 
Pvalb, Sst and Npy 11(Fig. 1e). A third round of clustering clearly separated the later into 
three distinct groups.  Of note, the  Npy expressing sub-cluster was enriched for 
additional markers of CGE-derived neurogliaform cells like Pnoc and Kit in contrast to 
the other two clusters 3,21 (Supplementary Fig. 3a). A fourth cluster, IN OB, with very few 
cells expressing the inhibitory neuronal marker Gad1, was enriched for the bHLH-
transcription factor encoding gene, Id2, the Activin A encoding gene, Inhba, Trdn, Ndnf 
and the biological process of neurogenesis (p=3.16e-2). These genes are markers for 
inhibitory neurons located in the olfactory bulbs of mice 3,21.   
Remarkably, we also identified one cluster that was enriched for transcription 
factors Pax6 and the T-box factor Eomes, respectively, which are involved in 
neurogenesis (Fig. 1e).  In order to further characterize the Eomes+ population, we 
compared these nuclei to gene expression data from adult mouse neural progenitor 
cells (NPC) 24. The Eomes+ nuclei clustered predominantly with NPCs and activated 
neural stem cells (aNSCs)  (Supplementary Fig. 3c). Taken together, our analysis of 
snRNA-seq of the adult forebrain, which uses intronic read counts and iterative 
clustering, identified 23 transcriptionally distinct clusters that reflect different cell types 
and region specific transcriptional profiles. 
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snRNA seq analysis of adult human frontal cortex and hippocampus illustrates 
glia cell heterogeneity    
We next sought to profile archived frozen human brain samples. In total, we 
profiled 10,609 nuclei from human frontal cortex (6,478 nuclei) and hippocampus (4,131 
nuclei).  On average we detected 761 genes and 960 transcripts per nucleus.  To 
perform downstream analysis, we combined data from both regions and identified 14 
clusters representing major classes of neuronal and non-neuronal cell types (Fig. 2a). 
Some of the populations were more prevalent either in the hippocampus or frontal 
cortex (Fig. 2b, c). We annotated clusters as described above based on expression of 
canonical marker genes (Supplementary Fig. 4a). Furthermore, we identified sets of 
genes enriched for each of the clusters (Fig 2d, Supplementary Table 3). The clusters 
and their transcriptional profiles were in overall concordance with single nuclei RNA-seq 
data from human hippocampus and frontal cortex using the DroNc-seq platform 
(Supplementary Fig. 4b)11.   
We identified two inhibitory and two excitatory neuron clusters in the merged 
data. Of note, the fraction of neurons was very low in the profiled hippocampus sample 
(Fig 2b). Therefore, the transcriptional profiles of the two excitatory neuron clusters 
predominantly resembled those of cortical projection neurons and subcortical projection 
neurons, as previously described12 (Supplementary Fig. 4c). The inhibitory neurons 
exhibited similar transcriptional profiles to VIP+ and SST+ interneuron subtypes 
described previously 8 (Supplementary Fig. 4c).    
The analysis also revealed two distinct clusters of astrocytes (ACI and II, Fig. 
2a,e). In order to understand what could be separating these two groups of astrocytes, 
we asked if they could come from different regions of the brain.  Astrocytes can be 
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distinguished by their location in grey and white matter as well as their function and 
morphology into protoplasmic and fibrous astrocyte populations 25,26.  Protoplasmic 
astrocytes, found in grey matter, have many processes and are connected by gap 
junctions; however, fibrous astrocytes, found in white matter, have fewer processes. 
Expression of GFAP, which encodes the glial fibrillary acidic protein, can be used as a 
molecular marker to distinguish astrocytes from grey and white matter, since it is higher 
expressed in white matter 26.  In line with this observation, GFAP was the top 
differentially expressed gene between AC I and AC II, with higher expression in AC II 
(Fig. 2e, Supplementary Fig. 4a).  Visualization of top differentially expressed genes, 
including previously described grey and white matter markers also suggested that AC I 
and AC II populations are likely representative of cells derived from grey and white 
matter, respectively (Fig. 2e). Next, we intersected the list of differentially expressed 
genes between AC I and II with bulk rna-seq data of white and grey matter astrocytes 
from the human frontal lobe 27.  This showed significant enrichment of the bulk grey 
matter transcriptional profile for AC I (p = 7.74e-06), and enrichment of the bulk white 
matter transcriptional profile for AC II (p=5.32e-4). Genes overexpressed in AC I 
exclusively overlapped with grey matter specific genes from bulk RNA-seq; whereas AC 
II exclusively overlapped with white matter specific genes from bulk RNA-seq 
(Supplementary Fig. 4e).  Previously, two astrocyte subtypes have been described in 
mice: a Gfap+ population originating from the glial limitans region of the brain, and a 
Mgfe8+ population consisting primarily of astrocytes evenly distributed around the 
cortex 23. Based on the set of marker genes described, the two astrocyte subtypes 
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identified in this study might resemble transcriptional signatures of these populations 
(Supplementary Fig. 4d). 
We also revealed four clusters of oligodendrocytes (ODG I-IV) and two clusters 
of oligodendrocyte precursor cells (OPC I, II) (Fig. 2a). Three of the ODG clusters were 
shared between hippocampus and frontal cortex whereas ODG II was only present in 
the hippocampus (Fig. 2b, c). In addition, cortical and hippocampal OPCs were also 
strikingly different (Fig. 2b,c). 
Oligodendrocyte heterogeneity in juvenile and adult mouse brains has been 
attributed to maturation of OPC to ODG 28.  Therefore, we asked if the differences 
between ODG clusters could be explained by ODG maturity in the human samples. 
Differential expression analysis between the four ODG clusters (Supplementary Table 
3) revealed significant enrichment for genes associated with the most mature 
oligodendrocytes found in the mouse brain (p = 0.02) in the hippocampus-specific ODG 
II.  Next, we performed pseudotime ordering of cells from the ODG and OPC clusters. 
The end points of the trajectory were occupied by OPC I, II and ODG II nuclei. Nuclei 
from ODG I, III and IV were located on the trajectory in between these two extremes. 
The four ODG clusters also showed significant differences in the median pseudo-times, 
a proxy for ODG maturity level (p < 0.005).  Based on this pseudotime analysis 
oligodendrocyte maturation seems to be reflected from young to mature in the order 
ODG III, ODG IV, ODG I and finally ODG II (Fig 2f). 
Next, we performed a comparison between the human and mouse data. We 
focused our analysis on cell clusters represented in both the merged data from human 
frontal cortex and hippocampus as well as the mouse forebrain. We excluded excitatory 
  20 
neurons from our analysis since the majority of these cells in the human dataset 
originated from the frontal cortex, and did not represent the diversity of excitatory 
neurons identified in the mouse forebrain. Using nuclei from MG, AC, ODG, OPC, IN2 in 
the mouse data set for the comparison, we first identified cluster-specific genes and 
then analyzed expression of orthologous genes in the human data.  The cell type 
specific expression of these genes was concordant between the two species (Fig 2g). 
We also further characterized AC and ODG clusters from the mouse forebrain. The 
transcriptional profile of mouse astrocytes was more similar to human white matter 
astrocytes (p = 0.03, fisher's-exact), and the transcriptional profile of mouse 
oligodendrocyte was similar to the more mature oligodendrocyte clusters by visual 
inspection (Fig. 2g). 
Intronic read based clustering shows increased specificity for cell clustering of 
single nuclei RNA-seq datasets in human heart ventricles 
Finally, we performed snRNA-seq on human cardiac ventricles. While single cell 
RNA-seq has been performed on mouse ventricles for the non-cardiomyocyte fraction 
and limited number of cardiomyocytes from human and mouse hearts using a plate 
based approach 29,30, there are no reports on high-throughput droplet-based single 
nuclear RNA-seq from frozen human cardiac ventricles. Several challenges exist in 
scRNA-seq profiling of cardiac tissue: it is difficult to encapsulate cardiomyocytes into 
droplets due to their size, and it is extremely challenging to isolate intact 
cardiomyocytes from frozen specimens. One solution is to purify cardiac nuclei prior to 
processing with a droplet based microfluidics platform.  Based on our previous 
experience working with cardiac tissues we found that tissue grinding does not 
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efficiently release cardiomyocyte nuclei. Thus, we have optimized nuclei isolation for 
snRNA-seq using the gentleMACS platform (see methods). 
We applied our technique to 4720 nuclei from human right (1927 nuclei) and left 
cardiac ventricles (2793 nuclei). On average we detected 384 genes and 502 transcripts 
per nucleus, allowing us to reveal 9 cell types (Fig 3a).  By focusing our clustering 
analysis on intronic reads, we observed significantly better cell-type separation than we 
would have using only exonic, or exonic and intronic reads (Fig 3a).  Notably, in the 
heart tissue, an intronic read driven clustering approach also allowed us to observe 
cluster specific expression of cardiomyocyte specific markers MYH6 and TTN 
(Supplementary Fig 5a).  This is in line with our initial hypothesis, that highly abundant 
RNA sticking to the outsides of isolated nuclei might confound clustering analysis.   
Based on analysis of marker genes we annotated all major ventricular cell types 
including (cardiomyocytes, adipocytes, endothelial cells, macrophages, fibroblasts, 
schwann cells, immune cells (T/NK cells), and a mixture of smooth muscle/pericytes) 
(Fig 3a,b). Cells from each ventricle clustered together; however, adipocytes were 
primarily derived from the right ventricular sample (Fig. 3c). Cell type specific gene 
expression of differentially expressed genes identified from our transcriptomic analysis, 
coupled with GO enrichment analysis, further validated cell type classifications for these 
nuclei populations (Fig 3b,d, Supplementary 5b, Supplementary Table 4).  We also 
performed gene set enrichment analysis on adipocytes, smooth muscle cells, 
macrophages  and NK/T cells,  all of which had broad GO enrichment terms, and found 
that these clusters were enriched for the hallmark adipogenesis genes (p=4.35 e-17), 
vascular smooth muscle contraction (p=6.75 e-9), hallmark inflammatory response 
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genes (p= 7.47 e-9), and hallmark interferon gamma response genes (p= 2.54 e-3), 
respectively.   
Next, we asked if there were differences between left and right ventricular 
cardiomyocytes. Subclustering of the cardiomyocyte cluster showed that the primary 
difference between these cells was their origin (left or right ventricle) (Supplementary 
Fig. 5c). Gene set enrichment analysis on genes differentially expressed between these 
two clusters, indicated that left ventricular cardiomyocytes were enriched for heart 
contraction, actin mediated cell contraction, and hallmark myogenesis genes; whereas, 
right ventricular cardiomyocytes were enriched for regulation of blood and circulation; 
regulation of blood pressure, and circulatory processes (Supplementary Fig. 5d, 
Supplementary Table 4). In addition, we observed that the number of transcripts and 
genes captured in left ventricular cardiomyocytes was significantly higher than the 
number of transcripts and genes captured in right ventricular cardiomyocytes, despite 
similar sequencing depth (Supplementary Fig. 5e). 
2.4 Discussion 
Single nuclei RNA-seq is a valid alternative to single cell RNA-seq 6,16–18.  
However, sparsity of nuclear RNA-seq data and free- floating mature cytoplasmic RNA 
molecules pose challenges for analysis. Compared to previous reports, which use 
exonic or a combination of intronic and exonic reads for clustering, we show that 
clustering based on intronic reads is advantageous when profiling tissues with high 
expression of cell-type specific RNAs.  In a recent comprehensive comparison of mouse 
brain single nuclei to matched single cells, it has been reported that the majority of 
intronic reads from single nuclei map to large genes with tissue specific expression, 
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implying that these reads likely contribute to biological cellular heterogeneity 16.  In line 
with this observation, we observe a much better separation of cell types when 
performing unsupervised clustering on gene expression data generated from intronic 
reads alone, versus both intronic and exonic reads. Ideally, by using intronic reads 
alone, we would be able to perform differential expression analysis between our 
clusters, and annotate our cell types using canonical marker genes.  However, many 
genes, such as those with a large 3’ end, or single-exon genes, are only captured when 
using reads mapping to exonic regions. Therefore, due to data sparsity, we bring back 
exonic reads for downstream analysis in order to annotate cell types with more 
confidence.  We observe that relative gene expression differences are still preserved 
between cell clusters, when including exonic reads which makes this approach viable 
for accurate cell type classification.   
The presented snRNA-seq approach allows us to capture diversity in the mouse 
and human brain and human heart.  In particular, using an intronic-read-based 
clustering approach compared to an approach using both intronic and exonic reads 
allows us to computationally reveal the cellular heterogeneity in these samples.  For the 
adult mouse forebrain, this allows to capture previously described spatially diverse 
neuronal subtypes.  In the human frontal cortex and hippocampus, we are able to tease 
apart excitatory neurons into subcortical and cortical projection neurons, inhibitory 
neurons into those that are expressing SST and VIP, and separate out oligodendrocytes 
based on their maturity level assessed by pseudotime analysis.  The detected neuronal 
subtypes are just a few of many subtypes that have been previously characterized in 
the human brain using snRNA-seq12. One of the reasons for the observed lower 
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complexity might be the limited cell number profiled as compared to this previous study. 
However, the type of heterogeneity that we observe in maturing oligodendrocytes has 
been described only in the mouse brain28.  In a study of the human brain, Lake et al are 
able to place oligodendrocyte progenitor cells and oligodendrocytes into a 
developmental trajectory; however, they were unable to separate the mature 
Oligodendrocyte (mOli) population into the mature Oligodendrocyte (mOL) populations 
observed in the mouse brain10.  We do not capture all of these mOL populations either; 
however, our analysis suggest that our hippocampal specific ODG cluster is similar to 
the most mature mOL population previously described in mouse, and the other ODG 
sub clusters we observe come from less mature mOL populations.  Finally, in the 
human heart we identified the major cardiac cell types. The non-cardiomyocyte cell 
types that we can characterize in human heart sample like immune, schwann, and 
endothelial subtypes, have been previously reported in a study of the non-
cardiomyocyte cells of the mouse heart30.   
2.5 Conclusions 
In summary, we present an intron read based approach that is more sensitive to 
deconvolve frozen tissue samples like brain and heart samples into their cellular 
constituents as compared to approaches including exonic reads. Not only can these 
single nuclei RNA-seq data be used to infer cell types, but they can also be used to 
track cell trajectories, best demonstrated in our analysis of human oligodendrocyte 
differentiation and maturation. As comprehensive references to characterize cell types 
form different tissues grow, data sparsity will become less of a challenge for cell type 
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annotation, and this snRNA-seq technique will be useful in the characterization of a 
variety of frozen biobanked clinical samples from control and diseased patients. 
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2.6 Figures 
Figure 2.1. snRNA-seq analysis of adult mouse forebrain recapitulates spatial neuronal 
heterogeneity and reveals neural stem cell like cell populations 
 
a T-SNE visualization of mouse adult forebrain annotated with cell type and number of cells(left); b 
Scaled UMI expression of inhibitory and excitatory neuron markers (Gad1, Slc17a7) ; c  Heatmap plotting 
row based z-score of average UMI expression in each cluster .  Enriched GO terms for cluster specific 
genes are on the right hand side; d Spearman correlation to previously published data 11 (see methods); 
e Sub-clustering of cortical and hippocampal interneurons into 8 clusters including an Eomes+ cluster; f 
Sub clustering of Pvalb+/Sst+/Npy 
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Figure 2.2 snRNA seq analysis of adult human frontal cortex and hippocampus illustrates 
glia cell heterogeneity    
 
a T-SNE visualization of human adult hippocampus and frontal cortex annotated with cell type and 
number of cells; b T-SNE visualization showing cells that come from the hippocampus.  Circled clusters 
predominantly contain cells from the hippocampus sample; c T-SNE visualization showing cells that come 
from the frontal cortex.  Circled clusters predominantly contain cells from the frontal cortex sample; d 
Heatmap plotting row based z-score of average UMI expression in each cluster .  Enriched GO terms for 
cluster specific genes are on the right hand side; e Scaled UMI gene expression of grey and white matter 
astrocyte specific markers projected onto identified astrocyte clusters;  f Predicted single-cell trajectory 
rooted at the OPC I/II cells(top); Violinplot of pseudotime estimates for cells in ODGI-IV and OPC I, 
II.  Dashed lines represent different quartiles, and the differences between the median estimated 
pseudotime for ODGI-IV are all statistically significant (bottom); g Heatmap displaying expression of cell 
type-specific genes in the mouse (left).  Heatmap displaying expression of orthologous human genes in 
corresponding cell types (right). Values plotted in the heatmap are the row-based z-score of average UMI 
expression in each cluster.    
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Figure 2.3 Intronic read based clustering shows increased specificity for cell clustering 
of single nuclei RNA-seq datasets in human heart ventricles 
 
a T-SNE visualization of human heart ventricles annotated with cell type and number of cells (left);  T-
SNE visualization of clustering results of human heart ventricles when using exonic and exonic+intronic 
reads (right).  b Heatmap plotting row based z-score of average UMI expression in each cluster 
.  Enriched GO terms for cluster specific genes are on the right hand side; c Cells in each cluster plotted 
by sample of origin (top). Tissue specific clusters are circled; Stacked bar plot showing the percentage of 
cells from each ventricle in each identified cell type (bottom); d Violin plots of UMI for cell type specific 
genes using gene expression values from all reads 
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2.7 Supplemental Figures 
 
 
Supplemental Figure 2.1 Experimental and computational workflow 
 
 
Supplemental Figure 2.1 Experimental and computational workflow 
a Brain tissues were homogenized in liquid nitrogen using mortar and pestle followed by nuclei 
permeablization and library preparation using a commercial droplet based scRNA-seq procedure (10x 
Genomics). b Cardiac ventricles were homogenized using gentleMACS (Miltenyi), since grinding was not 
sufficient to release cardiac nuclei. After nuclei permeablization, library preparation was conducted using 
a commercial droplet based scRNA-seq procedure (10x Genomics). c Assessment of barcode collision 
for a mixture of human and mouse nuclei. For ~2,000 nuclei the barcode collision rate was about 2.0 % 
which is within the specification provided by 10x Genomics for single cells. d. Computational analysis 
workflow flowchart. 
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Supplemental Figure 2.1 Experimental and computational workflow continued  
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Supplemental Figure 2.2 Clustering comparison using intronic and exonic reads vs. 
intronic reads 
 
Supplemental Figure 2.2 Clustering comparison using intronic and exonic reads vs. 
intronic reads 
a T-SNE plots of the adult mouse forebrain.  Right shows clustering results using reads that align to both 
exons and introns; left shows clustering results using only intronic reads b T-SNE plots of the human 
frontal cortex and hippocampus.  Right shows clustering results using reads that align to both exons and 
introns; left shows clustering results using only intronic reads c T-SNE plots of human heart 
ventricles.  Right shows clustering results using reads that align to both exons and introns; left shows 
clustering results using only intronic reads d) Top row are histograms of the length in base pairs (bp) of 
the last exon for genes used when you use only exonic reads, only intronic reads, or both exonic and 
intronic reads; bottom row are histograms of the number of exons for genes used when you use only 
exonic reads, only intronic reads, or both exonic and intronic reads 
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Supplemental Figure 2.3 snRNA-seq analysis of adult mouse forebrain recapitulates 
spatial neuronal heterogeneity and reveals neural stem cell like cell populations 
Supplemental Figure 2.3 snRNA-seq analysis of adult mouse forebrain recapitulates 
spatial neuronal heterogeneity and reveals neural stem cell like cell populations 
 
a Heatmap visualizing row-based z-score of average UMI for marker genes of previously defined 
interneuron subtypes (left); heatmap visualization row-based z-score of average UMI for marker genes of 
CGE-derived neurogliaform cells (middle); Scaled UMI expression of Pvalb, Npy, Sst in sub-clustered T-
SNE plot (right);  b Violin plots of UMI for cell type specific genes; c  Co-clustering of previously published 
NPC data 24 with our Eomes+ population.  Plot showing the percentage of cells of each cell type found in 
each cluster (top).  The size of the circle is proportional to the percentage of cells; cell types in grey font 
are cell types identified in previously published data; cell types in black font are cell types identified in our 
data.  The three bottom plots show a T-SNE visualization of the co-clustering and are colored by cell type 
or cluster ID.    
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Supplemental Figure 2.4 snRNA seq analysis of adult human frontal cortex and 
hippocampus illustrates glia cell heterogeneity 
a Violin plots of UMI for cell type specific genes; b Spearman correlation to previously published data 11 
(see methods); c Heatmap showing average scaled UMI of genes shown to be markers of SCPN & CPN 
Ex Neurons 12  (top left); Violinplot of UMI of genes specific to each excitatory neuron type (bottom 
left);  Heatmap showing average scaled UMI of genes shown to be markers of SST+ & VIP+ Inhibitory 
Neurons11 (top right); Violinplot of UMI of genes specific to each inhibitory neuronal type (bottom right); d 
Boxplot of genes that are markers of astrocyte subtypes in 27 ; e  Venn diagram showing intersect 
between genes differentially expressed between bulk white and grey matter and genes differentially 
expressed between AC I and AC II 
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Supplemental Figure 2.5  Intronic read based clustering shows increased specificity for 
cell clustering of single nuclei RNA-seq datasets in human heart ventricles 
 
a  T-SNE visualization of clustering using intronic reads vs all reads; expression (scaled UMI) of 
cardiomyocyte specific markers MYH6 & TTN  are highlighted in each plot.  Expression is calculated 
using only intronic reads (top), and using intronic & exonic reads (middle, bottom); b Violin plots of 
ventricular UMI data based on expression calculated from intronic reads alone.  These genes are markers 
of T/NK; c  Sub-clustering of ventricular cardiomyocyte cluster separating out the cells by tissue of origin; 
d  Bar plot of GO/GSEA terms enriched in cardiomyocytes of left and right ventricles; e Boxplots of 
number of genes in each cell type from each sample (p<.05 marked by *, p<.005 marked by **, p<.0005 
marked by ***, NS (not significant) (right); Boxplots of number of transcripts in each cell type from each 
sample (p<.05 marked by *, p<.005 marked by **, p<.0005 marked by ***, NS (not significant) (left); Sup 
1d: Gene set enrichment analysis of genes differentially expressed between left and right cardiomyocytes 
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2.8 Methods 
2.8.1 Data generation 
1.1 Tissue Collection 
Human dorsolateral prefrontal cortex and hippocampus tissue of a healthy 31 
year old male were obtained from the National Institute of Child Health and Human 
Development (NICHD) Brain Bank for Developmental Disorders. Ethics approval was 
obtained from the University Health Network and The Hospital for Sick Children for use 
of the tissues. Cardiac ventricles were from a 3 year healthy male described before as 
part of the Epigenome Roadmap Consortium collection (The Roadmap Epigenomics 
Consortium, 2015; Biomaterial provided by  Shin Lin, Stanford University). Adult mouse 
forebrain was harvested from 8-week old male C57BL/6NCrl mice (Charles River 
Laboratories) and flash frozen in liquid nitrogen separately. 
1.2 Nuclei isolation 
1.2.1 Brain tissue 
Brain tissues were ground in liquid nitrogen using mortar and pestle. Next, 10-30 
mg of ground tissues were incubated with 500 µl nuclei isolation buffer (2% BSA, 0.2% 
Triton-X cOmplete (Roche), 1 mM DTT, 0.2 U/µl RNAsin (Promega) in PBS) for 10 min 
at 4°C. After centrifugation with 500 x g for 5 min nuclei were resuspended in sort buffer 
(2 % BSA, 1 mM EDTA, 0.2 U/µl RNAsin (Promega) in PBS). Nuclei suspension was 
filtered before sorting. 
1.2.2 Cardiac ventricle tissue 
Nuclei from cardiac ventricles was isolated as described previously with minor 
modifications (cite). Frozen cardiac tissue was thawed on ice and submerged in 1 ml 
lysis buffer (5 mM CaCl2, 3 mM MgAc, 2 mM EDTA, 0.5 mM EGTA, 10 mM Tris-HCL, 
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pH 8). Next, ventricles were  homogenized using a gentleMACS dissociator (Miltenyi) 
with gentleMACS M tubes (Miltenyi) using the protocol “protein_01”. Next, 1 ml of lysis 
buffer supplemented with 0.4 % triton-X was added and the combined cell suspension 
was filtered. The filter was washed with 1 ml lysis buffer including 0.2 % triton-X to 
increase nuclei yield. The flow-through was centrifuged (500 x g, 5min) and 
resuspended in sort buffer. 
1.3 Nuclei sorting and single nuclei RNA-seq library preparation 
  Nuclei were sorted using a SH800 sorter (Sony) after staining with the DNA-dye 
DRAQ7 (3 µM, Cell Signalling Technologies). Sorted nuclei were pelleted (15 min, 1000 
x g) and resuspended in PBS containing 1 % BSA and 0.2 U/µl RNAsin (Promega), at a 
concentration of 1000 nuclei//µl. Single nuclei RNA-seq libraries were constructed using 
the Chromium™ Single Cell 3’ v2 Library kit (10x Genomics) according to manufacturer 
descriptions. Reverse transcription and other amplification steps were carried out on a 
T100 thermal cycler (Bio-Rad). After reverse transcription, GEMs (Gel beads in 
emulsion) were lysed and cDNA was cleaned up with MyOne Silane Beads (Thermo 
Fisher Scientific). Next, single stranded cDNA was PCR-amplified for 14 cycles and 
purified using SPRIselect Reagent Kit (Beckman Coulter). Next, cDNA was 
enzymatically fragmented followed by double size selection with SPRIselect Reagent Kit 
(200-700bp, 0.6x and 0.8x, Beckman Coulter). Subsequently, adaptors were ligated and 
libraries were constructed by PCR. Another round of double size selection was 
performed using SPRIselect Reagent Kit (200-700bp, Beckman Coulter). Final libraries 
were quantified using  Qubit® dsDNA HS Assay Kit (Thermo Fisher Scientific) and size 
distribution was measured using Tapestation (High Sensitivity D1000, Agilent). Average 
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fragment size of successful libraries was 500 bp. The libraries were loaded at a 
concentration of 13 pM and sequenced on a Hiseq 2500 sequencer (Illumina) with the 
following parameters (Read1 26 cycles; Index 1 8 cycles; Read 2 98 cycles). 
2.8.2 Data Analysis 
2.1 snRNA-seq alignment, clustering & marker gene identification 
Samples were mapped using the STAR aligner to the gencode version 27 
(GRCh38.p10) genome.  In order to retain intronic reads, we used the mapping pipeline 
used in 12, modifying it slightly to give mapping preference to exons, if these exons 
overlapped with intronic regions of other genes oriented in the same direction.  For 
downstream analysis, to deconvolve cell types and merge samples, we used the Seurat 
package in R 31,32. The following analysis was performed on a gene by cell matrix of 
UMIs obtained from reads mapping to intronic regions alone.  We first filtered out cells 
that had less than 200 expressed genes, and all genes that were expressed in ten or 
fewer cells.  In order to filter out potential doublets, we used a filter on the ratio of 
UMI/genes in all cells.  This ratio showed a bimodal distribution. Cells with a higher ratio 
of UMI/gene were filtered out.  We scaled each gene umi count by 1e4, normalized and 
log transformed the expression values in each cell 33, and then scaled to z scores for 
each gene across all cells. We then used a sparse svd algorithm 34 to decompose the 
scaled expression matrix, and then performed the the Barnes-hut implementation of 
TSNE.   For cluster identification we used the FindClusters function in the Seurat 
package which first identifies the k nearest-neighbors to calculate a shared nearest 
neighbor graph, and then uses the original Louvain algorithm for modularity based 
community detection. K parameter for k nearest neighbors was chosen to be k that best 
optimized the following validity indices (Dunn Index,  Davies-Bouldin Index, Silhouette 
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Coefficient). After cluster identification, we disregarded clusters with less than 10 cells, 
and mapped back gene expression onto cells, as if we had generated a gene by cell 
UMI matrix using intronic and exonic reads.  We then used Wilcoxon-rank-sum test to 
identify genes that were significantly upregulated in the cells in one cluster vs. all other 
cells. Clusters were kept if their cells showed at least 2 fold upregulation of a gene, and 
merged with another cluster if they did not.  
2.11 snRNA-seq alignment and quantification 
First we aligned our sequencing data using only reads that mapped to introns 
(reads representative of transcripts found within the nucleus), and clustered the 
resulting gene expression matrix to identify cell types.  Even though intronic reads alone 
are sufficient to accurately separate cell types, it was difficult to confidently annotate 
human and mouse brain cell types without including transcription factors, or genes that 
lack introns in our analysis.  Therefore, we projected back the gene expression values 
that would be obtained from aligning and clustering all reads onto our cells in order to 
perform downstream analysis. 
2.2 Comparison of single cell data to previously published data 
We first created a list of cell-type specific marker genes identified from our 
differential gene expression analysis on each of the human and mouse brain clusters.  
For these genes we calculated the pairwise spearman correlations between cell types 
identified in our data set and in the data set from 6. The cell-type’s averaged scaled UMI 
counts were used to calculate the correlation.      
2.3 Pseudotime Analysis 
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Pseudotime analysis was performed on cells from the two OPC and four ODG 
clusters using the Monocle package in R 35-37. 
2.4 Gene Ontology Analysis 
We used the cited publicly available databases 38-40  for GO Analysis and Gene 
Set Enrichment Analysis 
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CHAPTER 3: Inter and Intra tumor transcriptomic heterogeneity in Glioblastoma 
 
3.1 Abstract 
Glioblastoma is the most common form of primary brain tumor in adults and 
remains one of the deadliest of human cancers.  Intra-tumoral heterogeneity in 
glioblastomas remains a major challenge in therapeutic development. While single cell 
based RNA profiling has yielded insights into this heterogeneity, the resolution of these 
techniques is limited and the pertinence of RNA-based profiling to epigenetic landscape 
remains unclear. To better address these issues, we have developed and applied single 
nuclei ATAC-Seq (snATAC-Seq) methods to clinical glioblastoma specimens secured 
from distinct regions of a tumor and compared these profiles to those derived using 
single nuclei RNA-Seq (snRNA-Seq).   We found that snATAC-seq could identify CNVs 
at the single cell level with high resolution (20KB), and these CNVs define distinct tumor 
sub-populations in different geographic locations of the tumor.  Using aberrant CNVs as 
a marker for cells derived from the glioblastoma, we found significant representation of 
cells with aberrant CNVs that harbor transcriptomic profiles suggestive of normal 
oligodendrocyte progenitor cell and astrocytes, suggesting potential for these cells to be 
tumor cells of origin. Our results indicate a combination of snRNA-seq and snATAC-seq 
as a valuable molecular platform for characterization of glioblastoma heterogeneity  
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3.2 Introduction 
Gliomas refer to primary brain tumors that arise from neural stem cells or 
progenitor cells, and account for 28% of all brain tumors and 80% of all malignant 
tumors1.  These tumors are classified in terms of their severity (grade) and histology 
(astrocytic, oligodendroglial, ependymal).  Of these gliomas, the most severe (grade IV), 
which are found predominantly in older individuals are classified as glioblastomas, and 
account for the majority of gliomas2.  Individuals with Glioblastoma (GBM) have an 
extremely poor prognosis.  Median survival after diagnosis and with treatment is in the 
range of 12 to 15 months1.  Not only can GBM occur in many different regions of the 
brain, but different tumors can contain different molecular signatures.   
The cancer genome atlas (TCGA) made one of the largest efforts to characterize 
the molecular heterogeneity in GBM3,4.   Using 206 glioblastoma samples, TCGA’s pilot 
study uncovered three pathways commonly mutated in GBM (receptor tyrosine kinase 
signaling, p53 signaling, and RB signaling)3.  Shortly after, using the same GBM data, 
another study revealed four molecular subtypes defined by 840 genes, more specifically 
by mutations or copy number variants found in EGFR, NF1, PDGFRA, IDH14 . These 
molecular classifications helped describe inter-tumoral heterogeneity; however, due to 
the failure of many targeted therapies, which either inhibit EGFR or target the commonly 
mutated pathways in GBM, it is increasingly evident that we must deepen our 
understanding of intra-tumoral heterogeneity5. 
Single cell technologies are well suited to characterizing intra-tumoral 
heterogeneity, and have been used to study glioblastoma since 2014. In one of the first 
studies to perform scRNA-seq on GBM tumors, Patel et al looked at ~400 cells across 5 
different patients and showed that individual tumors, characterized as expressing the 
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molecular signature of only one of the four TCGA subtypes, actually were comprised of 
cells that expressed signatures of more than one TCGA subtype.  Furthermore, an 
increase in TCGA subtype heterogeneity was associated with decreased survival6.   
Francis et al used a different single cell technology (scDNA-sequencing) to identify and 
characterize clonal sub populations with different kinds of EGFR mutations7.  Several 
years later, another scRNA-seq study profiled ~3500 cells in 4 patients with the goal of 
characterizing inter and intra patient heterogeneity between neoplastic tumor cells at the 
periphery of a tumor versus cells at the glioblastoma tumor core.  Their study 
surprisingly revealed some commonalities between genes signatures of invading 
neoplastic cells8.  More recently, a study attempting to investigate the glioblastoma cell 
of origin used single cell sequencing to show that cells carrying mutations in the tumor 
free SVZ region of a patient’s brain can evolve and turn into the glioblastoma tumor9.   
While scRNA and scDNA sequencing technologies, which profile transcriptomic 
and genomic heterogeneity, have been used to study GBM, nobody has profiled 
another potentially therapeutically rewarding component of intra-tumoral heterogeneity-- 
single cell epigenomic heterogeneity. ATAC-seq, an epigenomic assay for profiling 
regions of open chromatin can be used to reveal active regulatory elements 
genomewide10.  Recently, a large effort to characterize open chromatin profiles in TCGA 
samples was made using this technology.11  This study described tissue and cancer 
specific drivers, and linked open chromatin peaks (intergenic regions of high chromatin 
accessibility) to genes that may be regulated by the accessibility of these peaks.  
Integrating scRNA-seq and scATAC-seq profiles of matched glioblastoma 
samples would allow for thorough classification of this disease since scRNA-seq profiles 
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would serve as a functional readout of the scATAC-seq profiles.  However, in order to 
achieve this goal, several computational challenges exist.  The biggest challenge stems 
from the cellular composition of glioblastoma tumor sections. In any given frozen tumor 
section, some fraction of the cells are actually cell types observed in the normal human 
brain, while others are the tumor cells, which often harbor mutations.  Previous studies 
have used the presence of profilable mutations to computationally separate out these 
cell types by either using single-cell RNA-seq to identify chromosomal arm level 
amplifications or deletions, or by identifying point-mutations using reads that span the 
mutated region6,12.  Experimentally cell-type specific markers have been used to 
differentiate non-neoplastic cells from other cells8.  Other major challenges are related 
to: combining single cell data across multiple patients, and teasing apart potential batch 
effects from true genetic variation between patients, and linking regions of high 
accessibility (ATAC-seq peaks) with genes that these peaks could be associated 
with13,14. 
In this study we performed snATAC-seq and snRNA-seq (single nuclear RNA-
sequencing) on flash frozen tissue from five different glioblastoma patients with the goal 
of characterizing transcriptional and chromatin accessibility profiles in subtypes of 
glioblastoma tumor cells.  Two patients provided sectional information representing 
proximity to the tumor core.  Using the generated single cell chromatin accessibility 
profiles, we first identified CNVs distinct to tumor cell populations and used these 
regions to identify tumor cells in our snRNA-seq profiles.  We then characterized 
transcriptional differences between sub-populations of tumor cells, and identified two 
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populations of astrocyte (ASC) and oligo-progenitor  (OPC) like cells, which could be 
potential “cells of origin.”   
Results 
Single nuclei were isolated from flash frozen tumor sections obtained from five 
different GBM patients (GBM1, GBM4, GBM9, GBM11, GBM12).  Five sections 
representative of distance away from the tumor core, were resected from GBM1, and 
four sections, also representative of this distance, were resected from GBM4.  These 
nuclei were used to perform single nuclear RNA-seq (snRNA-seq) and single nuclear 
ATAC-seq (snATAC-seq) (Fig 1a,b). We expected these tumor sections to contain 
tumor cells, as well as glial and neuronal cells typically found in the human brain. To 
computationally distinguish between these cell types, we co-clustered cells from each 
patient , for each assay, with normal cells from the human brain (frontal cortex and 
hippocampus) that were analyzed in chapter 2 (Fig 1c). 
Using the UMAP15 algorithm to visualize our clustering results, we identified 25 
clusters from our snATAC-seq profiles, and 18 clusters from our snRNA-seq profiles 
(Fig 1c).  These clusters represented normal glial and neuronal cells (astrocytes, 
microglia, oligodendrocytes, oligodendrocyte progenitor cells, inhibitory and excitatory 
neurons), as well as tumor sub-clusters. We found there to be 16 tumor sub-clusters in 
snATAC-seq and 8 tumor clusters in snRNA-seq (T1-T8).  In order to gain confidence in 
our snRNA-seq clustering results, we visualized and annotated cluster specific genes 
(Sup Fig 1a), and plotted signatures of normal cell types onto our single nuclear RNA-
seq profiles (Sup Fig 1b).   Enrichment of top differentially expressed genes between 
clusters corresponded well with our annotations; for example, microglia were enriched 
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for immune systems processes, and astrocytes and neurons were enriched for genes 
known to be upregulated in astrocytes and neurons (cahoy astrocytic; cahoy neuronal).  
Interestingly we also identified two populations (ASC-like and OPC-like) that were 
enriched for cell cycle and gliogenesis genes. We also tried several approaches to 
merging and clustering snRNA-seq data across all patient samples (Sup Fig 1c, 
methods) to see if we could achieve more biologically meaningful cluster separation 
13,16.  When co-clustering each patient sample with cells from the normal human brain, 
we observed a considerable number of cells that were “non-tumor” cell types (Sup Fig 
1d); therefore, we evaluated the validity of different clustering methods used to merge 
patient samples, by looking for clusters that contained cells from the normal human 
brain sample, as well as from the tumor sections (see methods).  The only approach 
that resulted in clusters containing cells from our GBM patients, as well as from our 
normal human brain sample, in similar proportions to what was observed in individual 
patient clustering, was an approach that used canonical correlation analysis 13.  It is still 
possible that this algorithm tried to over-fit the similarity between cells across multiple 
patients, but we were content with the cluster specific transcriptional signatures.   
From this analysis, we asked if we could identify clusters that were specific to 
tumor cells within the tumor sections.  By plotting the percentage of cells from each 
patient in each cluster (Fig 1d), we observed that the majority of tumor cell clusters from 
snATAC-seq were patient specific; however, the majority of tumor cell clusters from 
snRNA-seq were mixed across patients. To better understand if the patient specific 
clustering results from snATAC-seq profiles were truly patient specific or the result of 
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inter-sample variation, we also characterized differences in chromatin accessibility 
profiles between tumor sub-clusters 
Each tumor section sampled contained both cells that are normally present in the 
human brain, as well as tumor cells.  To confidently differentiate tumor from normal cells 
in our tumor sections, we co-clustered our tumor sections with normal cells, and plotted 
signatures of known cell types; however, we asked if we could also identify aberrant 
CNVs at the single cell level.  scRNA-seq has been used to previously identify CNVs; 
however, the resolution of this method is limited to the number of genes captured6.  
Since snRNA-seq is much sparser than scRNA-seq data, we asked if we could use 
chromatin accessibility data that profiles DNA instead of RNA, to identify CNVs at high 
resolution.  We were able to identify CNVs at high resolution (at least 30kb) in these 
patients (Fig 2a, 2b, see methods).  For instance, in GBM1, consistent with the patient’s 
medical report and whole-genome sequencing (WGS) data, we were able to identify 
amplifications of regions containing CCND1, EGFR, and LINC00676 , to name a few 
(Fig 2b, Supplementary Table 1).  Using the snATAC-seq data we identified 26 regions 
that were amplified across in at least one of our five patient samples.  Some regions, 
such as those containing EGFR and PDGFRA were amplified in multiple patients (Fig 
2c).  To understand if these CNVs were transcribed at higher levels, we looked at the 
cumulative expression of genes in these regions in our snRNA-seq clusters (Fig 2c).  
While the majority of amplified regions contained genes that were highly expressed in 
tumor clusters versus normal clusters, there were some exceptions.  We see that the 
amplified region containing EGFR is strongly expressed in two clusters containing cells 
primarily from GBM12, and is moderately expressed in two clusters containing cells 
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primarily from GBM4 and GBM1.  All three of these patients show amplification of EGFR 
in their medical reports.  We also observe high expression of CCND1 in clusters 
predominantly comprised of cells from patient 1 (Fig 2b).  However, FGF19, which is co-
amplified with CCND1 in the scATAC-seq data is not highly expressed in the snRNA-
seq data (Sup Fig 2a).  To better understand how frequently the CNVs we observed 
were represented in other patients, we also looked across GBM patients from the 
cancer genome atlas (TCGA) to characterize the frequency of mutations found in the 
genes contained in our amplified regions (Sup Fig 2b).  
After establishing that snATAC-seq profiles could be used to identify CNVs, we 
asked for the patients with sectional data (GBM1, GBM4), if the amplifications we 
observed were specific to a section of the tumor.  GBM4 was reported to carry both 
EGFR and PDGFRA amplifications, and from the chromatin accessibility profile, it 
became clear that these two amplifications were mutually exclusive, and largely section 
specific (Fig 3a).  To understand if these amplifications resulted in high expression of 
these genes, we first computationally isolated all the tumor cells from all patients, sub-
clustered these cells and then plotted expression of these genes in the tumor cells of 
GBM4 (Fig 3b, Sup Fig 3a).  The mutual exclusivity of these two amplifications was 
largely represented in our snRNA-seq data, and has also been previously reported 6 
(Fig 3a,b).  In GBM 1, the chromatin accessibility profiles showed amplification of 
CCND1 in all tumor cells; however, there also appeared to be clonal subpopulations 
that were section specific (Fig 3a).  When comparing our accessibility profiles to gene 
expression, we found that CCND1 was highly expressed in all tumor cells of GBM1; 
however, transcriptional (snRNA-seq) sub clustering of tumor cells in GBM1 was not 
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driven by CNV differences present in the four clones observed in the snATAC-seq 
clustering (Fig 3c, Sup 3a).  
Since clonal CNVs captured by open chromatin signatures were not driving the 
transcriptional heterogeneity of tumor cells, we asked if pre-defined molecular 
signatures could describe the observed transcriptional heterogeneity.  One such 
molecular signature is the TCGA derived GBM subtypes (neural, mesenchymal, pro-
neural and classical) identified from bulk RNA-sequencing17.  For each tumor cluster we 
calculated gene expression signals for all four TCGA defined molecular subtypes, using 
the snRNA-seq data, and clustered these results. The majority of cells carried a 
proneural or classical signature, one tumor sub-cluster, T5, which is also specific to 
GBM4, carried a strong mesenchymal signature, and T1, which is specific to GBM12, 
carried a strong neural signature. Overall, however, all tumor clusters were a mixture of 
these four molecular subtypes (Fig 4a).   To understand if the snRNA-seq tumor cells 
contained enrichment for any known pathways or gene-sets, we took all the tumor cells 
(T1-T8), sub-clustered them, and performed gene set enrichment analysis (Fig 4b, Sup 
3a).  Some pathways found to be enriched across patients included (MYC targets, G2M 
checkpoint, and mTORC1 signaling).  
Tumors are comprised of cells that initiate them (cell of origin) and cells that help 
them propagate (cancer stem cells).  Glioma cells of origin are believed to be cells that 
were originally normal glial cells, which acquired mutations that either prevented 
differentiation or promoted self-renewal18,19 . In order to better understand glioma 
development, studies have looked towards normal gliogenesis to draw parallels; 
specifically, they have looked at understanding parallels between the gliogenic switch 
  58 
and glioma-genesis, since glioma stem cells are more similar to glial precursor cells 
than neural stem cells19.  The gliogenic switch refers to the point in neural stem cell 
(NSC) development, during which expression of several transcription factors pushes the 
cell towards turning into an  (NFIA, SOX9) astrocyte precursor (APC) or  (OLIG2, 
SOX10) oligodendrocyte pre-cursor cell (OPC)19. Therefore, in order to understand 
which glial precursor populations were represented in each of our individual tumor 
sections, we characterized expression of the transcription factors involved in the 
gliogenic switch (Fig 4c).  GBM1 and 9 carried signatures of both OPC and APCs, and 
GBM 4, 11 and 12 carried a signature of cells on an astrocytic trajectory.   
In our snRNA-seq clustering results of all patient sections, we observed two 
populations consisting of astrocyte (ASC) like and oligodendrocyte progenitor cell 
(OPC) like cells (Fig 1d, Fig 4a).  We observed that GBM4 and 11, which carried a 
strong signal for APCs, also represented the majority of cells found in the ASC-like 
cluster.  Furthermore, GBM1 and GBM9, which carried a strong OPC signal, 
represented the majority of cells found in the OPC-like cluster. In order to understand if 
these OPC and ASC like cells could be potential cells of origin in these patients, we 
performed pseudotime analysis using the ASC-like, OPC-like, ASC, oligodendrocyte 
(ODG), OPC and tumor cells in GBM1,4 and 9, and the (ASC-like, ASC and tumor cells) 
in GBM 11,12 (Fig 4d, Sup Fig 4). In pseudotime trajectory plots, any end of the 
trajectory can be interpreted as the starting point “time 0.” However, since we know that 
normal ODG cells must be older than normal OPC cells in our tumor sections, we can 
use this to interpret these trajectories.  Using this interpretation, it appeared that the 
ASC-like and OPC-like populations could have given rise to the observed tumor 
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subpopulations.  In GBM 1, and 9 it was clear that the OPC-like cells could have given 
rise to the predominant tumor subtypes in those patients (T3,T4,T6,T8; T2).  In GBM 11 
we observed that the ASC-like population likely gave rise to the predominant tumor 
subpopulation (T4); however, in GBM 12, the majority of T7 cells appeared to be the 
same age as the ASC-like cells.  Finally, in GBM 4 the ASC or OPC-like cells could 
have both resulted in the observed tumor subpopulations. 
 While GBM4 didn’t show strong markers of normal gliogenesis towards the OPC 
and ODG lineages, it did contain a significant portion of cells that were classified to be 
OPC-like (22%).  Since it is believed that changes to the typical gliogenesis pathway 
lead to glioma formation, and that normal cell types, which are more susceptible to 
mutations, turn into tumor cells of origin, we asked what the differences were between 
OPC-like cells in GBM4 and normal OPCs1819.  We also looked at these differences in 
GBM 1,4 and 9, as well as the differences between ASC-like and normal astrocytes in 
GBM 1,4,11,12.  These transcriptional differences included increased expression of 
previously identified CNV genes (GBM1: CCND1, ORAOV1, ETV1 GBM4: EGFR 
GBM9: PDGFRA, GBM12: EGFR). (Sup Table 2).    
Discussion: 
The true transcriptional signature of a tumor cell varies at the inter and intra 
tumoral level; therefore, any method that studies the heterogeneity of these signatures 
must confidently distinguish tumor from other cells found in each patient.  Identification 
of known genetic abnormalities found in the tumor, such as CNVs, deletions or point-
mutations , at the single cell level, provides confidence  in cell characterization.  In our 
study, snATAC-seq allows for the identification of CNVs at high resolution. The 
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expression of genes found in these CNVs can further be investigated, at the single cell 
level, by using our snRNA-seq profiles.  In GBM1, not only were we able to identify 
clonal tumor sub-clusters, but we were also able to investigate the transcriptional 
significance of the co-amplification of a locus containing CCND1 and FGF19.  FGF19 is 
amplified in several other cancers including head and neck squamous cell carcinoma 
and breast 20,21.  In breast cancer, this gene has been commonly co-amplified with 
CCND1, and associated with poor patient prognosis.  Furthermore, expression of 
FGFR4, FGF19’s co-expressed receptor, has been correlated with resistance to the 
EGFR inhibitor erlotinib in glioblastoma cell lines22.  Taken together, these observations 
suggest that it would be important for patient treatment to know if a patient carried both 
an EGFR and FGF19 amplification.  In GBM 1, it appears that the amplification of 
FGF19 does not result in high levels of gene expression, and is likely amplified due to 
its proximity to the CCND1 locus.   
 The presence of sectional data from GBM1 and 4 allowed us to further 
investigate our high-resolution CNV calls, and ask if we observed sectional differences 
associated with section specific CNVs.  Interestingly, in GBM 4, we find mutually 
exclusive amplifications of PDGFRA and EGFR.  GBM is marked by mutations in RTKs, 
and one of the most commonly mutated pathways in GBM is the PI3K pathway 3.  
PDGFRA and EGFR, two genes found to be amplified in GBM4 are both part of this 
core pathway that regulates cellular proliferation23.  While these amplifications may 
appear to be distinct, they both lead to constitutive activation of the PI3K pathway.  In 
patients like GBM4, patients with multiple RTK mutations, anti-PDGFR and anti-EGFR 
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therapies have either failed or done poorly, suggesting that these patients would be 
prime candidates for combination therapies aimed at multiple RTKs24 
 While we were unable to identify cancer stem cells (CSC) by looking for known 
CSC markers, we were able to identify two cell types (ASC-like and OPC-like), 
represented in all patients, which could be potential cells of origin for the tumor cells 
analyzed in our tumor sections.  Compared to ASCs and OPCs found in the normal 
human brain, these cells exhibited higher expression of genes amplified in GBM 1,4,9 
and 12.  Both cancer stem cells and tumor cells of origin contribute to tumor 
progression, and are important to identify18. OPCs could serve as a cell of origin for 
glioma, due to their demonstrated plasticity—their ability to differentiate into astrocytes 
and oligodendrocytes based on external signaling19,25.  A recent study, however, 
showed that NSCs found in the SVZ are likely tumor cells of origin for glioblastomas9.  
The ASC-like and OPC-like cell types that we identified as potential cells of origin could 
have differentiated from NSCs found in regions of the brain not sampled in this study.   
 We have combined snATAC-seq and snRNA-seq to investigate inter and intra 
tumor heterogeneity in five patients.  Our snATAC-seq analysis has outlined a method 
for identifying CNVs at high resolution, as well as identifying clonal tumor 
subpopulations based on CNV signatures.  By combining this approach with snRNA-seq 
to better understand which amplified genes are actually over expressed in sub clonal 
populations, we provide an analysis framework that has implications for therapy. 
Furthermore, we provide insight into the transcriptional signatures, shared across five 
patients, of potential cells of origin in these tumor sections.  Future studies designed to 
give us a better understanding of these cells of origin and their open chromatin 
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landscape, as well as studies that investigate the open chromatin and transcriptomic 
landscapes of tumor sub clonal populations before and after treatment will be important 
to advance current therapies.   
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3.5 Experimental Procedures 
3.5.1 Data generation 
1.1 Tissue Collection 
Post-surgery flash frozen glioblastoma samples were obtained from Dr. Clark 
Chen .  The normal samples used in this study (Human dorsolateral prefrontal cortex 
and hippocampus tissue of a healthy 31 year old male) were obtained from the National 
Institute of Child Health and Human Development (NICHD) Brain Bank for 
Developmental Disorders. Ethics approval was obtained from the University Health 
Network and The Hospital for Sick Children for use of the tissues. 
1.2 Nuclei isolation 
  Brain tissues were ground in liquid nitrogen using mortar and pestle. Next, 10-30 
mg of ground tissues were incubated with 500 µl nuclei isolation buffer (2% BSA, 0.2% 
Triton-X cOmplete (Roche), 1 mM DTT, 0.2 U/µl RNAsin (Promega) in PBS) for 10 min 
at 4°C. After centrifugation with 500 x g for 5 min nuclei were resuspended in sort buffer 
(2 % BSA, 1 mM EDTA, 0.2 U/µl RNAsin (Promega) in PBS). Nuclei suspension was 
filtered before sorting. 
1.3 Nuclei sorting and single nuclei RNA-seq library preparation 
  Nuclei were sorted using a SH800 sorter (Sony) after staining with the DNA-dye 
DRAQ7 (3 µM, Cell Signalling Technologies). Sorted nuclei were pelleted (15 min, 1000 
x g) and resuspended in PBS containing 1 % BSA and 0.2 U/µl RNAsin (Promega), at a 
concentration of 1000 nuclei//µl. Single nuclei RNA-seq libraries were constructed using 
the Chromium™ Single Cell 3’ v2 Library kit (10x Genomics) according to manufacturer 
descriptions. Reverse transcription and other amplification steps were carried out on a 
T100 thermal cycler (Bio-Rad). After reverse transcription, GEMs (Gel beads in 
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emulsion) were lysed and cDNA was cleaned up with MyOne Silane Beads (Thermo 
Fisher Scientific). Next, single stranded cDNA was PCR-amplified for 14 cycles and 
purified using SPRIselect Reagent Kit (Beckman Coulter). Next, cDNA was 
enzymatically fragmented followed by double size selection with SPRIselect Reagent Kit 
(200-700bp, 0.6x and 0.8x, Beckman Coulter). Subsequently, adaptors were ligated and 
libraries were constructed by PCR. Another round of double size selection was 
performed using SPRIselect Reagent Kit (200-700bp, Beckman Coulter). Final libraries 
were quantified using  Qubit® dsDNA HS Assay Kit (Thermo Fisher Scientific) and size 
distribution was measured using Tapestation (High Sensitivity D1000, Agilent). Average 
fragment size of successful libraries was 500 bp. The libraries were loaded at a 
concentration of 13 pM and sequenced on a Hiseq 2500 sequencer (Illumina) with the 
following parameters (Read1 26 cycles; Index 1 8 cycles; Read 2 98 cycles).   
Single nuclear ATAC-seq was performed using the protocol outlined in Preissl et al 
201838.   
3.5.2 Data Analysis 
2.1 snRNA-seq alignment, clustering & marker gene identification 
  Samples were mapped using the STAR aligner to the gencode version 27 
(GRCh38.p10) genome.  In order to retain intronic reads, we used the mapping pipeline 
used in 7, modifying it slightly to give mapping preference to exons, if these exons 
overlapped with intronic regions of other genes oriented in the same direction.  For 
downstream analysis, to deconvolve cell types and merge samples, we used the Seurat 
package in R 33,34. The following analysis was performed on a gene by cell matrix of 
UMIs obtained from reads mapping to intronic regions alone.  We first filtered out cells 
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that had less than 200 expressed genes, and all genes that were expressed in ten or 
fewer cells.  In order to filter out potential doublets, we used a filter on the ratio of 
UMI/genes in all cells.  This ratio showed a bimodal distribution. Cells with a higher ratio 
of UMI/gene were filtered out.  We scaled each gene umi count by 1e4, normalized and 
log transformed the expression values in each cell 16, and then scaled to z scores for 
each gene across all cells. We then used a sparse svd algorithm 35 to decompose the 
scaled expression matrix, and then performed the Barnes-hut implementation of TSNE.   
For cluster identification we used the FindClusters function in the Seurat package which 
first identifies the k nearest-neighbors to calculate a shared nearest neighbor graph, and 
then uses the original Louvain algorithm for modularity based community detection. K 
parameter for k nearest neighbors was chosen to be k that best optimized the following 
validity indices (Dunn Index, Davies-Bouldin Index, Silhouette Coefficient). After cluster 
identification, we disregarded clusters with less than 10 cells, and mapped back gene 
expression onto cells, as if we had generated a gene by cell UMI matrix using intronic 
and exonic reads.  We then used Wilcoxon-rank-sum test to identify genes that were 
significantly upregulated in the cells in one cluster vs. all other cells. Clusters were kept 
if their cells showed at least 2 fold up-regulation of a gene, and merged with another 
cluster if they did not.  
2.2 snATAC-seq alignement, clustering & marker gene identification 
  Samples were mapped to the hg38 genome, and downstream analysis was 
performed using the SnapATAC pipeline39. 
2.3 Comparing different approaches to snRNA-seq clustering across patients 
The snRNA-seq clustering results in Fig 1 are the clustering results of Seurat’s 
MultiCCA algorithm, designed specifically for integrating single cell data across different 
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conditions, technologies and species. For Sup Fig 1c: We also used harmony,16 another 
algorithm designed to account for variation across samples/conditions in scRNA-seq 
data.  We applied this algorithm to the sparse singular value decomposition of the 
scaled UMI count matrix (merged across all patients), and to the principal components 
of the scaled UMI count matrix (merged across all patients).  We also applied singular 
value decomposition to the scaled UMI matrix (merged across all patients) and used 
those components to perform graph-based clustering.   
   
2.4 Pseudotime Analysis 
  Pseudotime analysis on cells from each patient was performed using the 
Monocle package in R40–42 
2.5 Plotting gene expression of normal cell type signatures 
  Using the set of top differentially identified genes from single cell analysis of the 
human brain in chapter 2, we defined genes signatures for astrocytes, oligodendrocyte, 
oligodendrocyte progenitor cells, microglia and neurons.  We took the average 
expression of these genes in each cell, calculated a z-score based on all cells in the 
sample, and plotted this value onto our snRNA-seq clustering results 
 
2.6 Gene Set Enrichment Analysis 
  We used the cited publicly available databases43,44  for GO Analysis and Gene 
Set Enrichment Analysis 
2.7 CNV Identification form snATAC-seq data  
  In order to detect genomic amplifications from snATAC-Seq, we first got the 
aggregate counts of all cells within each cluster for 10kb bins across the entire genome. 
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In order to identify genomic amplifications, we generated a background based on 5000 
random 10kb bins that overlap with open chromatin peaks in that cluster. We then 
calculated a p-value for each 10kb bin based on the number of 10kb windows in the 
background greater than the observed value and divided by 5000. We first used a cut-
off of 0.01 to select the 10kb bins enriched ATAC-Seq signal and merged the bins. We 
further filtered any regions < 30kb to remove highly accessible promoter regions to 
determine the regions of genomic amplifications. These were then validated against the 
amplifications called using bulk WGS data from the tumor sample.	 
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3.6 Figures 
Figure 3.1: snRNA-seq and snATAC-seq profiles of GBM Patients  
A) Schematic outlining the protocols used to generate each sample B) Statistical metrics about each 
sample (median number of UMI from snRNA-seq; median number of reads from snATAC-seq) C) UMAP 
visualization of snATAC-seq data (left) and snRNA-seq data (right) co-clustered with unmatched normal 
brain tissue from the human frontal cortex and hippocampus; Top figures are colored grey for normal cell 
types and colored for tumor clusters; Bottom clusters are colored by patient and section of origin D) Bar-
plot indicating relative percentage of cells in a given cluster from each patient (Patient1, Patient4, Patient 
9, Patient 11, Patient 12, Normal Sample). 
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Figure 3.2: CNV Identification using snATAC-seq profiles  
A) CNV identification workflow B) scATAC-seq profiles in normal and tumor cells in patient 1 at three 
regions identified to contain different CNVs; Bottom track is a whole genome sequencing track from this 
patient C) Heatmaps displaying column z-scores of average chromatin open-ness(left) and average gene 
expression (right) at 26 regions identified to carry CNVs across patients.  Rows represent cluster identity 
from original clustering of all patients merged with normal cells; columns represent the 26 amplified 
regions  
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Figure 3.3: snRNA-seq and snATAC-seq profiles of GBM Patients  
A) Clustering results of clustering snATAC profiles from GBM4 (patient4) and GBM1(patient1) (left); 
clustering results shaded in by proximity to tumor core (darker colors are closer to tumor core)(middle); 
chromatin accessibility profiles of the promoters of amplified genes (right) B) Expression of amplified 
genes in GBM4; region that is boxed contains cells from patient 4 C) snRNA-seq profiles of tumor cells 
only from all patients, highlighting GBM1; cells are colored by cluster (left) and by clones described in 
snATAC-seq data (middle); clustering results on right display one GBM1 clone at a time  
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Figure 3.4 Inter and intra-tumoral transcriptional heterogeneity 
 
Figure 3.4: Inter and intra-tumoral transcriptional heterogeneity 
A) Heatmap z-scored by column showing TCGA subtypes of tumor cells based on cumulative gene 
expression of TCGA molecular subtypes; columns are colored by initial clustering (left); UMAP plot of 
patient clustering colored by TCGA subtype (middle; UMAP plot of initial clustering results (right); B) 
Clustering of tumor cells in all patients annotated with gene set/pathway enrichment C) Expression of 
markers of typical gliogenesis in the human brain that lead to an astrocytic trajectory (top) and 
oligodendrocyte trajectory (bottom) D) Pseudotime trajectories of tumor cells, ASC, ASC-like, ODG, OPC, 
and OPC-like cells in patients GBM1, GBM4, GBM9 ; T1-T8 represent tumor subtypes  
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3.7 Supplemental Figures 
Supplemental Figure 3.1 snRNA-seq GBM patient clustering 
A) Heatmap showing cluster specific gene expression and enrichment of select go terms B) Gene 
expression signatures of normal glial and neuronal cell types in the human brain plotted onto snRNA-seq 
clustering results C) Clustering results of different techniques to merge snRNA-seq data across all 
patients  D) snRNA-seq clustering results of each individual patient with normal frontal cortex & 
hippocampus samples; red represents patient cells and grey represents normal brain cells  
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Supplemental Figure 3.1 snRNA-seq GBM patient clustering continued  
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Supplemental Figure 3.2 Characterization of snATAC-seq identified CNVs 
 
Supplemental Figure  3.2 Characterization of snATAC-seq identified CNVs 
A) FGF19 expression plotted on snRNA-seq clustering results.  Scale is in unique molecular identifiers 
(UMI) B) Chart detailing presence of an amplification (red) or deletion (blue) at EGFR and other genes 
found to be amplified from snATAC-seq data  
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Supplemental Figure 3.3 snRNA-seq clustering of tumor cells from all patients  
 
 
Supplemental Figure 3.3 Inter and intra-tumoral transcriptional heterogeneity 
A) snRNA-seq clustering of only tumor cells identified across all patients; clusters are colored in by 
sample of origin (left);  same clustering results as left, but clusters are colored in by cluster ID (right)   
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Supplemental Figure 3.4 Pseudotime Analysis of ASC-Like cells in GBM11 &12 
 
 
 
Supplemental Figure 3.4 Pseudotime Analysis of ASC-Like cells in GBM11 &12 
A) Pseudotime trajectory profiles of ASC, ASC-Like and tumor cells in GBM11 (left) and GBM12 (right).   
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Appendix: Hydroxymethylation Landscapes in Human Embryonic Cell Lineages 
and Adult Tissues 
This appendix contains an exploratory correlative analysis on hydroxymethylation, 
which was the focus of my thesis prior to single cell transcriptomic analysis.   
A.1 Summary   
Hydroxymethylcytosine is an intermediate in the DNA de-methylation pathway; 
however its role in gene regulation has not been clearly elucidated.  In order to better 
understand this modification, its genomic distribution needs to be characterized, and 
until several years ago, a method to quantify this mark at base-pair resolution did not 
exist. By profiling this mark in early embryonic cells and adult tissues, we characterize 
its genomic patterns at various genomic features, thus revealing characteristics of 
5hmC that can be investigated in future studies.  In particular we focus on enhancers 
and intergenic regions: We identify regions genome-wide containing elevated levels of 
5hmC, which are enriched at exonic versus promoter regions, and at enhancers, and 
we show that changes in 5hmC and mC at enhancers are predictive of differentiation-
induced changes in enhancer state.   
 
A.2 Introduction 
Hydroxymethylation is an epigenetic mark, whose role in gene regulation has not 
been clearly elucidated.  While previous studies have shown that 5hmc plays an 
important role in embryonic development, the nature of this role remains to be 
understood.   TET proteins catalyze the oxidation of 5-methylcytosine (5mC) to 5-
hydroxymethylcytosine (5hmC), leading to an unmethylated cytosine through to a series 
of less stable intermediaries (5fC or 5caC) 1.  5hmC is often thought to play a passive 
role as a bystander in gene regulation, existing primarily as an oxidation product of 5mC 
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and as an intermediate in the 5mC demethylation pathway 2,3  In contrast, some 
evidence suggests that 5hmC may play a more active role by directly influencing gene 
expression 4–6. 
In order to better understand this modification, its baseline genomic distribution 
needs to be characterized.  Until several years ago, a method to quantify 5hmC at base 
pair resolution did not exist 7.  Previous methods were either non-specific, of much 
lower resolution, or jointly reported methylation and hydroxymethylation levels.   By 
using TAB-Seq, Yu et al. created base resolution maps for 5hmC in human embryonic 
stem cells (hESCs).  A useful reference, this map also showed that 5hmC and 5mC 
tended to be enriched at enhancers, and their levels are inversely correlated near 
transcription factor binding sites.  The dynamic nature of methylation and 
hydroxymethylation observed at these cis-regulatory elements suggested that 5hmC 
could be regulating gene expression by acting on cis-regulatory regions. Several other 
studies have also quantified 5hmC, with the goal of elucidating its functional role. 
Collectively, these studies have shown that this mark is found in a variety of species as 
well as tissue types, and that it is enriched at enhancers and genes 8. This suggests a 
functional role for this mark in gene regulation 8,9 . 
In this study we characterize 5hmC at base-pair resolution in 5 embryonic cell 
types and 5 adult tissues to provide a reference for future studies. The 5 cell types are 
part of a human embryonic stem cell (H1) and H1-derived system thoroughly 
characterized by Xie et al10.  Each of these derived lineages represents key stages in 
early development, and has been profiled for various other epigenetic marks including 
(H3K27ac, H3K4me1, and 5mC).  The 5 adult tissues have also been profiled for 
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various epigenetic marks11, and enhancers in these tissues have been defined.  While 
dynamic DNA methylation has been shown to occur primarily during early development, 
this property has only been shown to occur in adult tissues in some signaling 
pathways12.  Therefore by providing comprehensive maps of 5hmC in adult tissues, as 
well as cells in different stages of early development, we can gain deeper insight into 
the potential roles of this epigenetic mark.  Furthermore, 5hmC has been shown to 
serve as a biomarker for disease 13,14.  In order to understand how to use 5hmC to 
distinguish between aberrant and disease phenotypes, the base line profiles of 5hmC in 
normal tissues and cells need to be determined.  
A.3 Results 
A.3.1 Genomewide Basepair Resolution Characterization of 5hmC 
By performing TAB-seq, we quantified 5-hydroxymethyl cytosine at base pair 
resolution in 5 human cell types (human embryonic cells (H1); mesendoderm (MES); 
trophoblast-like (TBL); neural progenitor cells (NPC); mesenchymal stem cells (MSC)), 
and 5 Adult tissues (lung, liver, pancreas, spleen, hippocampus) (Fig 1a).  Consistent 
with previous studies that have quantified 5hmC, with affinity purification based 
methods, and with TAB-seq in the brain, we observed high levels of 5hmC in the 
Hippocampus (Fig 1b) 15.  We also observed higher levels of 5hmC in adult tissues than 
in ES cells (ES cells mean hmC: 2.4%; ES cells standard deviation hmC: 3.16%; Adult 
Tissue mean hmC: 7.02%; Adult Tissue standard deviation hmC: 10.74%; Mann-
Whitney U test (p=0); KS test (p=0); Fig S1a). Genomewide, we found 5hmC to be 
variable across tissues. To explore the nature of this variation, we examined the 
distribution of 5hmC at various genomic regions in our various cell and tissue types (Fig 
1c).  In agreement with previous studies 7,8, we observed an enrichment for 5hmC at 
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promoters, intergenic regions, and enhancers, as compared to random (See 
supplementary Table 1a).   
 
A.3.2 Genomewide Characterization of 5hmC levels across Human Tissue and H1 & 
Derived Cell Lineages 
 
To better understand the distribution of 5hmC genome-wide, we characterized 
cytosines into low and high regions of 5hmC (Appendix Sup Fig 2a).  We then identified 
958 focal regions of elevated 5hmC (High State Domains of hmC (HD-hmC)), 
commonly marked in all cells and tissues profiled (Appendix Fig 2a).  Since these 
regions were common to all of our cell and tissue types, we characterized the 
distribution of hmC at these HD-hmC in adult tissues and cell types (Appendix Fig 2b), 
as well as their sizes (Appendix Fig 2c).  Examining the enrichment of these regions at 
various genomics features, we found HD-hmC regions to be enriched at enhancers in 
the H1 and H1 derived cells, as well as in adult tissues, as well as at intergenic regions 
(Appendix Fig 2d, Appendix Table S2).  Furthermore, in comparison to random 
background regions in the genome of similar size, HD-hmC regions where 
approximately 3 times as likely to fall at exonic regions versus promoter regions (tss +/-
250)(p = 4.8e-4).  HD-hmC regions also showed the greatest enrichment at H1 and H1 
derived enhancers (Appendix Table S2).   
Since we found HD-hmC regions to be both enriched at intergenic regions, as 
well as, commonly located on the gene body instead of the promoter, we tried to gain 
more insight into the types of genes found at these regions by conducting GO analysis 
using genes located in HD-hmC regions (Appendix Sup Table 1B,C).  We found that 
these genes were enriched for biological processes related to negative regulation of 
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cellular, metabolic, and biological processes (p = 8.5e-3, p=1.1e-3, p = 3.13e-2), and in 
particular, negative regulation of transcription of DNA-templated transcription, 
transcription from the RNA polymerase II promoter, and gene expression (p= 3.25e-2, 
p=4.10e-3,p=4.19e-2).  Additionally, we found these genes to be enriched for the 
cadherin and wnt signaling pathways (p = 1.08e-7, p=1.49e-5)  
A.3.3 Hydroxymethylation at Enhancers 
Since we observed earlier that hmC was enriched at enhancer regions, an 
observation consistent with previous studies conducted in human ES cells7,8,16, we next 
sought to characterize 5hmC at these genomic regions. Enhancer states are typically 
characterized into four categories (inactive, primed, poised, and active), and are defined 
by several chromatin marks. Poised enhancers are most prevalent in ES cells, and are 
characterized by repressive marks in regions of open chromatin; whereas, active 
enhancers are characterized by activating marks, such as H3K27ac and RNA 
Polymerase II 17.  Since poised enhancers are common in ES cells, we focused further 
analysis on identifying differences between 5hmC and enhancers in active and poised 
states. 
We previously profiled histone marks across human embryonic and derived 
lineages. Using this data, we identified active and poised enhancers (enhancers marked 
with both H3K4me1 and H3K27ac and those marked with only H3K4me1, 
respectively)10.  Additionally, we used a previously identified set of active enhancers in 
adult tissue for tissue enhancer analysis 11. To identify target genes for these enhancer, 
we used the nearest gene, located upstream, within, or downstream of the enhancer.   
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A.3.4 Enhancer body 5hmC and Gene Expression 
Previous studies have suggested that enhancer methylation might affect gene 
expression through various mechanisms 18.  We wondered if enhancer 5hmC is 
predictive target gene expression. Using a set of enhancers found across all of cells and 
tissues (excluding hippocampus), we correlated enhancer 5hmC and target gene 
expression for each gene.  At a 16% FDR rate, we identified 6% of enhancers as having 
strong correlations (positive and negative) between enhancer 5hmC and gene 
expression (Appendix Fig 4a, Appendix Sup Table 1q).  While this does not imply that 
the changes in enhancer 5hmC cause the changes in target gene expression, it 
suggests that the two are either directly related, or related through some confounding 
factor.  GO analysis of these genes revealed an enrichment in several biological 
processes, including, RNA splicing related terms, chromatin and chromosomal 
organization; the top molecular functions that were enriched were those related to RNA 
and nucleic acid binding (Appendix Sup Table 1r). 
 
A.3.5 Predicting Changes in Enhancer State 
Enhancer state is determined by the presence of histone marks and open 
chromatin.  However, the mechanisms that cause changes in enhancer state are an 
area for exploration.  In particular, the role of 5hmC in this context is yet to be 
understood.   One hypothesis with mounting support is that TET activity results in 
demethylation, accompanied by an increase in hydroxymethylation at the enhancer, 
which then is associated with changes in enhancer state 18. 
In order to further investigate the role of 5hmC at enhancers, and whether this is 
a passive or active role, we focused on enhancers that changed in state (active to 
poised or poised to active) in H1 and derived lineages. First, we characterized 5hmC 
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levels at enhancers identified as active or poised in each cell type (Appendix Fig 4b), 
and observed that the distribution of 5hmC at active enhancers is significantly different 
than that of poised enhancers (Appendix Fig 4c, KS Test, p = 2e-202) in H1 and H1 
derived cells. 5hmC levels are higher in active enhancers, in comparison to poised 
enhancers, which is consistent with previous studies 7,19.  Next, we looked across 
enhancers that changed in state, from H1 to a derived lineage, to understand if changes 
in enhancer 5hmC, could potentially be related to changes in enhancer activity.  We 
noticed that, for enhancers that switched from an active to a poised state during 
differentiation, changes in 5hmC were significantly different (KS test, p <1e-25 for all cell 
types) for enhancers that switched from a poised to an active state (Appendix Fig 4d, 
Appendix Sup Fig 4b). 
Since these distributions were different, we next focused on whether differences 
in mC (delta mC) and 5hmC (delta 5hmC) between enhancers were predictive of 
switches in enhancer state.  By using changes in 5hmC and 5mC levels at enhancer 
regions, classified as switching from an active or poised to a poised or active state, 
between H1 and a given derived cell line, we were able to measure how well each of 
these epigenetic marks could independently predict changes in enhancer state 
(Appendix Sup Fig 4 f-j; Appendix Fig 4e).  In order to understand if changes in 5hmC 
and 5mC levels, at a given enhancer, which changed in state between H1 and a derived 
cell line, were correlated in each cell type, we looked at the spearman correlations of 
these two changes in each of the H1 derived lineages.  If this correlation is negative, 
this would indicate that the difference in mC levels and hmC levels, at a given state-
changing enhancer, were inversely correlated; if this correlation is positive, this would 
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likely indicate that the rate at which cytosines were being methylated, and the rate at 
which mCs were being converted to 5hmC was much greater than the rate at which 
5hmC was being converted to further oxidized forms (5fc,caC).  Notably, we found that 
in MSC, this correlation was negative and strong (-.79) (Appendix Sup Fig 4f).  Next, we 
independently checked the correlations of changes in 5hmC, and changes in 5mC with 
change in enhancer state (Appendix Sup Fig 4f).  A positive correlation would indicate 
that an increase in the difference of 5hmC levels or difference in 5mC levels was 
associated with a switch from a poised state in H1, to an active state in a derived cell 
type; a negative correlation would indicate the opposite.  All correlations were 
significant, and we found that for delta 5hmC, this correlation was weak and negative for 
all cell types but TBL, for which it was weak and positive, and for delta mC, this 
correlation was weak and negative for all cell type but MSC, for which it was weak and 
positive.  Since none of the correlations between delta mC/hmC and change in 
enhancer state were extremely strong, we next applied a simple classifier to measure 
the predictive-ness of the change in both of the epigenetic marks (mC, 5hmC) in 
predicting change in enhancer state (Appendix Fig 4e, Appendix Sup Fig 4g).   
To assess the relative importance of changes in enhancer 5hmC/mC enhancer-
body in predicting changes in enhancer chromatin state, we examined how well a 
combination of these marks could predict this change by using a linear SVM (Appendix 
Fig 4e, Appendix Sup Fig g-j).  We found that in all cell types, changes in either 5hmC 
or 5mC individually, at the enhancer body of enhancers that changed in state between 
H1 and a derived cell line, were better predictors of changes in enhancer state, than 
using a combination of the two marks (Appendix Fig 4d).   
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To understand the unexpected positive correlation between delta 5hmC  with 
delta mC in NPCs, we looked at the relationship of 5hmC and mC at enhancers 
genomewide.  Heatmaps of H1 derived cell types indicate a seemingly parabolic 
relationship between enhancer mC and 5hmC (Appendix Fig 4e, Appendix Sup Fig 
4e).  For both active and poised enhancers with low methylation, there is a positive 
correlation between enhancer 5hmC and mC. However, for high levels of mC, there is a 
negative correlation between an enhancer 5hmC and mC.  This suggests that a certain 
level of enhancer mC must be present, before the rate at which 5hmC oxidation is faster 
than the rate at which mC is being oxidized into 5hmC.  We calculated this “methylation 
turning point” (Appendix Sup Fig 4d) for each cell type, and found that this level was 
lower for active enhancers, than for poised enhancers.  Since we were curious about 
the NPC enhancers that changed in state, following differentiation from H1, we also 
calculated this turning point for all enhancers that changed in state, in each cell 
type.  We found this turning point to be higher in enhancers that changed form a poised 
state in H1 to an active state in NPC, as opposed to enhancers that changed from an 
active state in H1 to a poised state in NPC, explaining the positive correlation we 
observed earlier between changes in 5hmC and mC between enhancers that change in 
state from H1 to the NPC lineage.   In all other cell types this turning point was higher 
for enhancers that changed from an active state in H1 to a poised state in the derived 
lineage, as opposed to enhancers that changed from a poised state in H1 to an active 
state in the derived lineage.   
A.4 Discussion 
We observed an enrichment of HD-hmC regions at enhancers, as well as at 
exonic regions as opposed to promoter regions.  The enrichment for HD-hmC at active 
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enhancers; however, is consistent with previous studies showing high levels of hmC at 
enhancers7,8,16.  The enrichment of genes found at HD-hmC in the Cadherin and WNT 
signaling pathways is interesting; however, since we did not observe a strong 
correlation between gene-body hmC and gene expression for most genes, there is not 
enough evidence to suggest that gene-body hmC levels could be directly impacting 
gene expression. 
In H1 and H1 derived cells genes with a significant correlation between gene 
body hmC and gene expression that are enriched for biological processes related to 
gene regulation, including regulation of gene expression, splicing, chromosome 
organization, and RNA polymerase activity, also showed a strong correlation between 
gene body mC and gene expression, indicating, that if methylation or 
hydroxymethylation are playing a role in regulating these genes, the role of mC is 
probably stronger than the role of hmC.  In Adult Tissues, where dynamic DNA 
methylation is known to be less prevalent, genes with a strong correlation between 
gene-body hmC and gene expression, but not gene body mC and gene expression are 
enriched for biological functions related to splicing, chromatin organization and SAM 
dependent methyl-transferase activity.  This suggests that perhaps, hmC has a distinct 
role from mC, if any, in potentially regulating these genes. 
The role of individual TET proteins at enhancers is a current area for exploration 
20.  However, it has been shown that TET2 is influential in maintaining 5hmC at 
enhancers 21,22.  Consistent with this observation, we observed that TBL enhancers 
(active and poised), had the highest levels of 5hmC, compared to other lineage specific 
enhancers, and the expression of TET2 was highest in the TBL cell type. Our 
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observations of mC and 5hmC profiles at active and poised enhancers in ES cells 
suggests that a certain level of enhancer mC must be present, before the rate at which 
5hmC is being converted back into C is faster than the rate at which mC is being 
demethylated into 5hmC. Additionally, it appears that the level of mC that must be 
present for this to happen is higher in MSC cells than other H1 derived cell types.  
If changes in mc and 5hmC are predictive of changes in enhancer state, this 
suggests that the loss or gain of these epigenetic marks is either causal, or the change 
in enhancer state is causing a change in these marks.  Our results show that the 
separate predictive abilities of enhancer-body changes in mC and 5hmC, between H1 
and derived lineages, in predicting changes in enhancer activity, are relatively similar for 
most cell types, except for NPC & MSC. This suggests that if 5hmC is playing an active 
role in the processes that either drive or result from changes in enhancer state, and is 
not purely a byproduct of DNA demethylation at enhancers, the role of 5hmC is 
relatively minor. However, in MSCs, since there is a strong inverse correlation between 
changes in enhancer-body 5hmC and changes in enhancer-body mC, but changes in 
enhancer-body 5hmC are a much better predictor of change in enhancer activity, 5hmC 
is likely playing an active role, in this cell type, in the biological process that either drive, 
or result from change in enhancer activity.  This resonates with some hypotheses where 
enhancer-body 5hmC prevents repressive histone marks from binding onto enhancers, 
in order to regulate enhancer state and gene activity 18. 
These baseline profiles of 5hmC in 5 adult tissues and 5 cell lines serve as a 
reference for others to study 5hmC, and have allowed us to attempt to identify potential 
roles of this epigenetic mark in gene regulation, which can be investigated in future 
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studies.  In the broader context of biomedical research, 5hmC has been shown to act as 
a biomarker for disease stage and outcome for certain diseases13.  Therefore, baseline 
profiles of this mark could have a long-term translational use, by assisting researchers 
in designing assays to distinguish between normal and aberrant phenotypes. 
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A.5  Appendix Figures 
 
Appendix Fig 1 Genomewide Basepair Resolution Characterization of 5hmC 
A)  UCSC Genome Browser visual representation of dynamic, base-pair resolution of hmC B) Violinplots 
of genome-wide distribution of hmC in adult tissues and H1 and H1 derived lineages C) hmC distributions 
at cell-type specific enhancers (left); promoters (tss +/- 1kb) (center); intergenic regions (right)  
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Appendix Fig 2 Genomewide Characterization of common regions of elevated hmC 
across Human Tissue and H1 & Derived Cell Lineages  
A) Visual representation, of a typical HDhmC region (focal region of elevated 5hmC) 
B) Distribution of hmC at all HDhmC regions in H1 and H1 derived cell lines and adult tissues 
C) Size distribution of HDhmC regions  (subset out the zoomed in region)  
D) Enrichment of  HD-hmC regions at various genomic features in comparison to random size-matched 
regions (fischer’s exact test used for determining significance)  
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Appendix Fig 3 Gene-body hmC Variation   
A) Gene-body hmC profiles of genes found to have highly variable gene-body hmC in H1 and H1 derived 
cells and adult tissues, respectively (variability determined by PCA on gene-body hmC). Values in 
heatmaps are first normalized by gene (row) and then clustered by gene.   
B) Bi-clustering of gene by gene spearman correlations across all H1 and H1 derived cell types, for genes 
with highly variable gene-body hmC in H1 and H1 derived cells.  Values in heatmap are spearman 
correlations. 
C) Distribution of spearman correlations of gene-body hmC and expression in H1 and H1 derived Cells 
(green) and Adult Tissues (red), with corresponding random distributions 
D) Gene-body hmC and expression profiles for genes found to be correlated (p <=.015; spearman 
correlation = -1 or 1) in H1 and H1 derived cells (top) and adult tissues (bottom).  Genes with a significant 
correlation between gene-body hmC and expression in H1 and H1 derived cells tends to show a positive 
correlation; whereas, those in adult tissues tend to show a negative correlation.  
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Appendix Fig 4 Enhancer hmC  
A) Distribution of spearman correlations between cell & tissue-type specific enhancer hmC and 
expression of the nearest genes to the enhancer.   
B) Distribution of hmC distribution at cell-type specific active and poised enhancers for each H1 and H1 
derived cell type.   
C) Distribution of hmC at all cell-type specific active and poised enhancers in H1 and H1 derived cells.   
D)  Changes in hmC and mC between enhancers that either switch from a poised state to H1, to an active 
state in MSC, or an active state in H1, to a poised state in MSC (left).   
E)  ROC curve on left, showing AUC for the “simple classifier”  (higher AUC indicates better performance) 
; ROC curve on right, with averaged AUCs for each cell type,  indicating performance of an SVM in 
utilizing changes in enhancer body hmC and mC to predict changes in enhancer state. (See S4f-S4j for 
more details)   
F) Left shows mC & hmC profiles at all active/poised enhancers for NPC; compared to enhancers that 
change in state between H1 and NPC (right) (See S4d,e for profiles of other cell types).   
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Appendix Sup Fig S1 
A) Genomewide distribution of hmC in H1 and H1 derived cells (left); in Adult Tissues (right).  Adult 
Tissues have significantly higher levels of hmC.  B) hmC levels at various genomic features in Adult 
Tissues (left) and H1 and H1 derived cells (right).    
 
Appendix Sup Fig S2 
A) Distribution of hmC genomewide; at regions classified by our hmm implementation as “high” 
and “low” in hmC.  B) Plot showing likelihood of observed hmC values given different values for 
“K” (number of states) used in our hmm implementation.   
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Appendix Sup Fig S3 
 
A) PCA Plots for PCA on Gene-body hmC in H1 and H1 derived Cells (Left); in Human Tissue (right); in 
all cell and tissue types (bottom) B) PCA plots for PCA on Gene-body mC in H1 and H1 derived cells 
(left); in Human Tissue (right); C) Distribution of Spearman correlations for genes found to have a 
significant correlation between gene-body hmC and expression across all 10 cell and tissue types, with 
corresponding random distribution (left).  Heatmap of gene expression and hmC for the significantly 
correlated genes (FDR = 16%) (right).   
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Appendix Sup Fig 4  
A) Enhancer size distributions for active and poised enhancers in H1 and derived  
B) Distributions of changes in hmC for enhancers that changes in state between H1 and each derived 
lineage.  All differences in distributions of delta enhancer hmC are significantly different and p-values are 
listed in the figure (KS test).  
C) Distributions of changes in mC for enhancers that changes in state between H1 and each derived 
lineage.  All differences in distributions of delta enhancer hmC are significantly different and p-values are 
listed in the figure (KS test). 
D) Methylation Turning Point of all cell-type specific enhancers in H1 and H1 derived cells (active and 
poised), compared to cell-type specific enhancers that change in state between H1 and a derived lineage. 
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Appendix Sup Fig 4 Continued 
E) mC & hmC profiles at cell-type specific enhancers, for those that change in state between H1 
and a derived lineage ( top), and for all enhancers (active and poised), within H1 and H1 derived 
cell types(bottom). C) Spearman correlations of delta hmC between state changing enhancers; 
delta mC between state changing enhancers; and changes in enhancer state for all derived 
lineages (Top).  Below is a table summarizing spearman correlations shown on top.   
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Appendix Sup Fig 4 Continued 
G) Table summarizing the average performance, after 10 fold cross validation, of the simple classifier on 
hmC and mC independently, as well as the performance of both the Linear SVM and Random Forest 
(Extra Trees Classifier) when using both epigenetic marks (mC & hmC).  
H) Precision and recall of Linear SVM on predicting changes in enhancer state, using 10 fold cross 
validation (left); Precision and recall of Random Forest (Extra trees classifier) on predicting changes in 
enhancer state, using 10 fold cross validation (right).   
I) ROC curves for the Linear SVM on predicting changes in enhancer state, for each cell type, using 10 
fold cross validation.  
J)ROC curves for the Extra Trees classifier on predicting changes in enhancer state, for each cell type, 
using 10 fold cross validation. 
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A.6 Methods 
A.6.1 Data Processing  
RNA-seq processing 
  Publicly available RNA-seq data from10  was aligned to hg18, using bowtie, and 
quantified using cufflinks.  Human Tissue Expression data was obtained from GEO 
(GSE16256). Human Tissue data was mapped to hg18. 
hmC and mC processing   
  We used novoalign to map the H1 and derived cells, and bismark to map the 
Adult Tissues to the hg18 genome.  Basecalls with a depth of less than then 10 and 
PHRED score below 20 were excluded from all analysis.   
A.6.2 Data Analysis  
Calculation of hmC at genomic features  
  Cytosine basecalls were summed and divided by average depth across gene-
body (genes defined in HG18); across enhancer body (active and poised enhancers in 
H1 derived were defined by presence of H3K27ac and H3k4me1, or H3k4me1, 
respectively10; enhancers in adult tissues were defined by 11.Background at each 
genomic feature was calculated by shuffling cytosine basecalls.   
Identification of HD-hmC regions  
  In order to identify genomic regions containing continuous cytosines that have an 
increased level of hmC, relative to the regions around them, we used a HMM.  Since we 
wanted to identify regions that had this property across all of our tissues/cells, we 
applied the hmm to a merged data set, where the cumulative number of cytosines and 
depth were merged.  In order to figure out how many states to use in the HMM, we 
calculated a score for each state ranging from 3 to 9.  We chose 9 states to get a clear 
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delineation between observations (hmC levels at each cytosine) in the lowest and 
highest states (Appendix Sup Fig 2). 
Genomewide classification of hmC levels & HD-hmC detection:   
  We applied a hidden markov model, assuming that the underlying distribution of 
the merged base-calls was a mixture of 9 gaussian distributions (using the python 
library scikit-learn implementation of GMM-HMM), to merged cytosine base calls, across 
the ten tissues.  Cytosine base-calls corresponding with the state associated with the 
highest levels of hmC were classified as “high hmC bases.”   See Appendix Sup Fig2 for 
the distribution of hmC levels at cytosines classified as low and high.  Consecutive base 
pairs in the same (high or low state) were merged to identify larger domains of hmC.  
Domains in the state coinciding with the highest levels of hmC were termed “HD-
hmC.”  Since we wanted to filter for regions with high levels of hmC, we used a cutoff for 
the minimum amount of hmC that must be contained by every cytosine in a genomic 
region termed as HD-hmC. This cutoff was determined based on the figure above, and 
was set as 10%.  Additionally, we observed that median size of these regions was much 
smaller than the mean size of these regions, so in order to use a more representative 
set of regions, we chose to the top 50% of HD-hmC regions, in terms of their sizes.   
Enrichment analysis of HD-hmC at various genomic features was calculated 
using Fischer’s Exact test.  5 set containing 958 random regions, sized match to HD-
hmC regions were pooled together and overlapped with each of the genomic features 
below to calculate the odds-ratios/p-values observed below: 
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Appendix Table S2: 
 
Gene Enrichment of Genes Falling in HDhmC  
  GO analysis was performed using Panther  23 (Appendix Sup Table 1c). Genes 
overlapped by any of the 958 HDhmC regions were compared against a background set 
of genes (genes overlapped by any of the 5 sets of 958 random, size matched HDhmC 
regions).   
Gene-body hmC  
  We first filtered our gene set to genes with hmC values above a minimum 
threshold in ES cells and Adult Tissues, respectively.  This threshold was determined 
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using the fully methylated TAB-seq treated pUC19 control.  Since this control should 
theoretically contain no hydroxymethylation, we first calculated TAB-seq values for 
these cytosines, and then used 2*(variance in these hmC values for each cell type) to 
serve as a minimum hmC threshold in each cell/tissue type.  Genes containing above 
this “minimum threshold” in at least one cell/tissue type, were kept for further analysis. 
  PCA-We used the python library scikit learn’s implementation of PCA, and 
normalized FPKM and hmC matrices, prior to doing PCA (“whiten” = True). The full set 
of genes mapped to hg19 were used for FPKM values, and the full set of genes from 
hg18 were used for gene body hmC calculations.  Top hits from PCA were defined as 
genes in the 95th percentile for magnitude of their loadings on PC1.  The list of these 
genes in H1 and H1 derived cells, and adult tissues can be found in appendix 
supplementary tables (1b,c).  See Appendix Sup Fig 3 for PCA plots of gene-body hmC 
and mC  in H1 and H1 derived Cells and Adult Tissues. 
  We also looked at how well PC1 and PC2 explain the variance in gene 
expression (RNA-seq) in the same set of genes.  Table below contains the percent of 
variation among the cells and/or tissue types that each PC explains: 
 
 
When identifying genes that had a strong spearman correlation of gene-body hmC, 
across the H1 and H1 derived cell lines, we kept genes whose average spearman 
correlation across the cell types, between itself and all other genes, was greater than or 
equal to .6.   
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Correlations of hmC and Gene Expression 
   We calculated the spearman correlations for each gene across all tissues.  Our 
random set used to calculate FDR, was created by shuffling FPKM values, across and 
within cell/tissue types.  Genes identified as significantly correlated across all 10 
cell/tissue types were identified using a 16%FDR.  Genes identified as significantly 
correlated across H1 and H1 derived cells and Adult Tissues had (p<=.05) where p was 
determined by the randomized distribution for each set of cells and tissues.   
 
Enhancer body hmC  
Genebody hmC and Target Gene Expression Correlations 
   A set of enhancers identified by Leung et al. 2015, common to 
H1,MES,TBL,NPC,MSC,Lung,Liver,Pancreas,Spleen was used to define enhancers (2 
kb regions).  Form this list the nearest gene within, upstream, or downstream to the 
enhancer was identified from all genes in hg18.   
Enhancer hmC and mC  
  Methylation Turning Point was calculated using python’s numpy library’s curve fit 
function.  The inflection point of this function was calculated, and used as the 
“methylation” turning point.  (See Appendix Sup Fig 4) 
Enhancer State Switching Predictions 
Feature Correlations 
   In order to determine how well each feature (change in hmC, change in mC) was 
correlated with change in enhancer state, we looked at the spearman correlations in 
each tissue type(See S4f for correlations). 
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Simple Classifier  
   In order to understand the predictive-ness of each mark independently, we 
applied a simple classifier to delta hmC and delta mC respectively.  Delta hmC and 
delta mC values were binarized based on whether or not they were positive or negative.  
These binary values (predictions), were compared to changes in enhancer state (true 
classification), which had also been binarized based on whether or not they were 
switching from an active to poised, or a poised to active state, between H1 and a 
derived lineage.  ROC curves were calculated by comparing the predictions to the true 
classification. (ROC curve is in Fig 4e and average performance is in Appendix Sup Fig 
4g). 
Linear-SVM and Random Forest for Classification of Changes in Enhancer State 
   In order to use both delta hmC and delta mC to predict changes in enhancer 
state, we assessed the performance of two classifiers (Linear SVM and Random Forest) 
on each cell type.  Using 10 fold cross validation, we compared the precision and recall 
of each classifier, and we compared the average rocs.  From this it appeared that the 
SVM performed better.  The python library scikit-learn’s implementations of linearSVM 
and ExtraTreesClassifier were used to perform the analysis).  (See Appendix Sup Fig 4 
for average performance ,ROC curves and other performance metrics). 
 
A.7 Acknowledgements 
Gary Hon and Miao Yu created TAB-seq libraries to generate hmC maps in these cell 
lines and tissues.  Siddarth Selvaraj, Gary Hon, and Anugraha Raman mapped the 
TAB-seq sequencing data.  Dr. Joseph Costello provided the hippocampal tissue.  
Yupeng He provided the bisulfite sequencing data for the adult tissues. 
  121 
A.8  References  
1. Pastor, W. A., Aravind, L. & Rao, A. TETonic shift: Biological roles of TET proteins in DNA 
demethylation and transcription. Nat. Rev. Mol. Cell Biol. (2013). doi:10.1038/nrm3589 
 
2. Gu, T. P., Guo, F., Yang, H., Wu, H. P., Xu, G. F., Liu, W., Xie, Z. G., Shi, L., He, X., Jin, S. G., 
Iqbal, K., Shi, Y. G., Deng, Z., Szabó, P. E., Pfeifer, G. P., Li, J. & Xu, G. L. The role of Tet3 DNA 
dioxygenase in epigenetic reprogramming by oocytes. Nature (2011). doi:10.1038/nature10443 
 
3. Branco, M. R., Ficz, G. & Reik, W. Uncovering the role of 5-hydroxymethylcytosine in the 
epigenome. Nat. Rev. Genet. (2012). doi:10.1038/nrg3080 
 
4. Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. 
M., Liu, D. R., Aravind, L. & Rao, A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in 
mammalian DNA by MLL partner TET1. Science (80-. ). (2009). doi:10.1126/science.1170116 
 
5. Valinluck, V. & Sowers, L. C. Endogenous cytosine damage products alter the site selectivity of 
human DNA maintenance methyltransferase DNMT1. Cancer Res. (2007). doi:10.1158/0008-
5472.CAN-06-3123 
 
6. Wu, H., D’Alessio, A. C., Ito, S., Wang, Z., Cui, K., Zhao, K., Sun, Y. E. & Zhang, Y. Genome-wide 
analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional 
regulation in mouse embryonic stem cells. Genes Dev. (2011). doi:10.1101/gad.2036011 
 
7. Yu, M., Hon, G. C., Szulwach, K. E., Song, C. X., Zhang, L., Kim, A., Li, X., Dai, Q., Shen, Y., 
Park, B., Min, J. H., Jin, P., Ren, B. & He, C. Base-resolution analysis of 5-hydroxymethylcytosine 
in the mammalian genome. Cell (2012). doi:10.1016/j.cell.2012.04.027 
 
8. Szulwach, K. E., Li, X., Li, Y., Song, C. X., Han, J. W., Kim, S. S., Namburi, S., Hermetz, K., Kim, 
J. J., Rudd, M. K., Yoon, Y. S., Ren, B., He, C. & Jin, P. Integrating 5-hydroxymethylcytosine into 
the epigenomic landscape of human embryonic stem cells. PLoS Genet. (2011). 
doi:10.1371/journal.pgen.1002154 
9. Szwagierczak, A., Bultmann, S., Schmidt, C. S., Spada, F. & Leonhardt, H. Sensitive enzymatic 
quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res. (2010). 
doi:10.1093/nar/gkq684 
 
10. Xie, W., Schultz, M. D., Lister, R., Hou, Z., Rajagopal, N., Ray, P., Whitaker, J. W., Tian, S., 
Hawkins, R. D., Leung, D., Yang, H., Wang, T., Lee, A. Y., Swanson, S. A., Zhang, J., Zhu, Y., 
Kim, A., Nery, J. R., Urich, M. A., Kuan, S., Yen, C. A., Klugman, S., Yu, P., Suknuntha, K., 
Propson, N. E., Chen, H., Edsall, L. E., Wagner, U., Li, Y., Ye, Z., Kulkarni, A., Xuan, Z., Chung, 
W. Y., Chi, N. C., Antosiewicz-Bourget, J. E., Slukvin, I., Stewart, R., Zhang, M. Q., Wang, W., 
Thomson, J. A., Ecker, J. R. & Ren, B. Epigenomic analysis of multilineage differentiation of 
human embryonic stem cells. Cell (2013). doi:10.1016/j.cell.2013.04.022 
 
11. Leung, D., Jung, I., Rajagopal, N., Schmitt, A., Selvaraj, S., Lee, A. Y., Yen, C. A., Lin, S., Lin, Y., 
Qiu, Y., Xie, W., Yue, F., Hariharan, M., Ray, P., Kuan, S., Edsall, L., Yang, H., Chi, N. C., Zhang, 
M. Q., Ecker, J. R. & Ren, B. Integrative analysis of haplotype-resolved epigenomes across 
human tissues. Nature (2015). doi:10.1038/nature14217 
 
12. Bhutani, N., Burns, D. M. & Blau, H. M. DNA demethylation dynamics. Cell (2011). 
doi:10.1016/j.cell.2011.08.042 
 
13. Thomson, J. P., Hunter, J. M., Lempiäinen, H., Müller, A., Terranova, R., Moggs, J. G. & Meehan, 
R. R. Dynamic changes in 5-hydroxymethylation signatures underpin early and late events in drug 
exposed liver. Nucleic Acids Res. (2013). doi:10.1093/nar/gkt232 
 
  122 
14. Li, W., Zhang, X., Lu, X., You, L., Song, Y., Luo, Z., Zhang, J., Nie, J., Zheng, W., Xu, D., Wang, 
Y., Dong, Y., Yu, S., Hong, J., Shi, J., Hao, H., Luo, F., Hua, L., Wang, P., Qian, X., Yuan, F., Wei, 
L., Cui, M., Zhang, T., Liao, Q., Dai, M., Liu, Z., Chen, G., Meckel, K., Adhikari, S., Jia, G., 
Bissonnette, M. B., Zhang, X., Zhao, Y., Zhang, W., He, C. & Liu, J. 5-Hydroxymethylcytosine 
signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. Cell Res. 
(2017). doi:10.1038/cr.2017.121 
 
15. Ruzov, A., Tsenkina, Y., Serio, A., Dudnakova, T., Fletcher, J., Bai, Y., Chebotareva, T., Pells, S., 
Hannoun, Z., Sullivan, G., Chandran, S., Hay, D. C., Bradley, M., Wilmut, I. & De Sousa, P. 
Lineage-specific distribution of high levels of genomic 5-hydroxymethylcytosine in mammalian 
development. Cell Res. (2011). doi:10.1038/cr.2011.113 
 
16. Stroud, H., Feng, S., Morey Kinney, S., Pradhan, S. & Jacobsen, S. E. 5-Hydroxymethylcytosine is 
associated with enhancers and gene bodies in human embryonic stem cells. Genome Biol. (2011). 
doi:10.1186/gb-2011-12-6-r54 
 
17. Heinz, S., Romanoski, C. E., Benner, C. & Glass, C. K. The selection and function of cell type-
specific enhancers. Nat. Rev. Mol. Cell Biol. (2015). doi:10.1038/nrm3949 
 
18. Calo, E. & Wysocka, J. Modification of Enhancer Chromatin: What, How, and Why? Mol. Cell 
(2013). doi:10.1016/j.molcel.2013.01.038 
 
19. Sérandour, A. A., Avner, S., Oger, F., Bizot, M., Percevault, F., Lucchetti-Miganeh, C., Palierne, 
G., Gheeraert, C., Barloy-Hubler, F., Péron, C. Le, Madigou, T., Durand, E., Froguel, P., Staels, 
B., Lefebvre, P., Métivier, R., Eeckhoute, J. & Salbert, G. Dynamic hydroxymethylation of 
deoxyribonucleic acid marks differentiation-associated enhancers. Nucleic Acids Res. (2012). 
doi:10.1093/nar/gks595 
 
20. Scourzic, L., Mouly, E. & Bernard, O. A. TET proteins and the control of cytosine demethylation in 
cancer. Genome Med. (2015). doi:10.1186/s13073-015-0134-6 
 
21. Hon, G. C., Song, C. X., Du, T., Jin, F., Selvaraj, S., Lee, A. Y., Yen, C. A., Ye, Z., Mao, S. Q., 
Wang, B. A., Kuan, S., Edsall, L. E., Zhao, B. S., Xu, G. L., He, C. & Ren, B. 5mC oxidation by 
Tet2 modulates enhancer activity and timing of transcriptome reprogramming during 
differentiation. Mol. Cell (2014). doi:10.1016/j.molcel.2014.08.026 
 
22. Putiri, E. L., Tiedemann, R. L., Thompson, J. J., Liu, C., Ho, T., Choi, J. H. & Robertson, K. D. 
Distinct and overlapping control of 5-methylcytosine and 5-hydroxymethylcytosine by the TET 
proteins in human cancer cells. Genome Biol. (2014). doi:10.1186/gb-2014-15-6-r81 
 
